var title_f5_54_5984="Histology lung 2B answer";
var content_f5_54_5984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides immitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swartz-Lamkin's wet mount of cocciodioides immitis from a fungal culture on Sabouraud's agar (x400). Barrel-shaped arthrospores are found in the mycelial phase of this organism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5984=[""].join("\n");
var outline_f5_54_5984=null;
var title_f5_54_5985="Hysteroscopic viewing angles";
var content_f5_54_5985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Hysteroscope with different viewing angles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5985=[""].join("\n");
var outline_f5_54_5985=null;
var title_f5_54_5986="Drivers with CHD";
var content_f5_54_5986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81399%7EPC%2F67184%7EPC%2F56525%7EPC%2F51053%7EPC%2F77026%7EPC%2F79800%7EPC%2F52146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81399%7EPC%2F67184%7EPC%2F56525%7EPC%2F51053%7EPC%2F77026%7EPC%2F79800%7EPC%2F52146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with known CHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic/functional",
"       </td>",
"       <td class=\"subtitle1\">",
"        Certification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Re-certification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Post MI",
"       </td>",
"       <td rowspan=\"12\">",
"        <p>",
"         Risk of recurrent major cardiac event highest within the first months post-MI",
"        </p>",
"        <p>",
"         Drivers in a rehabilitation program can receive comprehensive secondary prevention therapy",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"       <td rowspan=\"6\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Recurrent angina symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Post-MI ejection fraction &lt;40 percent (by echocardiogram or ventriculogram)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abnormal ETT demonstrated prior to planned work return",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic changes on rest ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Poor tolerance to current cardiovascular medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Biennial ETT at minimum (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"        <p>",
"         Cardiologist examination recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 2 months post-MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cleared by cardiologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - No angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Post-MI ejection fraction &ge;40 percent (by echocardiogram or ventriculogram)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Tolerance to current cardiovascular medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Angina pectoris",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Lower end of spectrum among CHD patients for risk of adverse clinical outcomes",
"        </p>",
"        <p>",
"         Condition usually implies at least one coronary artery has hemodynamically significant narrowing",
"        </p>",
"       </td>",
"       <td>",
"        Yes, if asymptomatic",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Biennial ETT at minimum (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"        <p>",
"         Cardiologist examination recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Rest angina or change in angina pattern within 3 months of examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abnormal ETT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic changes on rest ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Intolerance to cardiovascular therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        Post PCI",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         Rapid recovery for elective PCIs for stable angina",
"        </p>",
"        <p>",
"         Delayed re-stenosis is the major PCI limitation and requires intensive secondary prevention",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Recommend Cardiologist examination",
"        </p>",
"        <p>",
"         Biennial ETT (if test positive or inconclusive, imaging stress test may be indicated)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 1 week after procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cardiologist's approval and tolerance to medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - ETT 3 to 6 months after PCI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        No if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Incomplete healing or complication at vascular access site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Rest angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ischemic ECG changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Post Coronary Artery Bypass Surgery (CABG)",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Delay in return to work to allow sternal incision healing",
"        </p>",
"        <p>",
"         Because of increasing risk of graft closure over time, ETT is obtained",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         After 5 years: Annual ETT",
"        </p>",
"        <p>",
"         Imaging stress test may be indicated",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - At least 3 months after CABG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - LVEF &ge;40 percent post CABG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Approval by cardiologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Asymptomatic and tolerance to medications",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal, R, Braunstein, J, Connolly, H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with risk for CHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asymptomatic, healthy",
"      </td>",
"      <td>",
"       <p>",
"        Low CHD event risk.",
"       </p>",
"       <p>",
"        Assess for clinically apparent risk factors.",
"       </p>",
"       <p>",
"        Use, when possible, Framingham risk score model to predict 10-year CHD event risk",
"       </p>",
"       <p>",
"        Increasing age is a surrogate marker for increasing atherosclerotic plaque burden",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Yes, if asymptomatic.",
"       </p>",
"       <p>",
"        Rarely disqualifying alone.",
"       </p>",
"      </td>",
"      <td>",
"       Biennial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       <p>",
"        Asymptomatic, high risk person (as designated by CHD risk-equivalent condition)*",
"       </p>",
"       <p>",
"        Asymptomatic, high risk person &gt;45 years with multiple risk factors for CHD",
"       </p>",
"      </td>",
"      <td rowspan=\"5\">",
"       <p>",
"        Sub-clinical coronary atherosclerosis is a concern",
"       </p>",
"       <p>",
"        High-risk status requires close physician follow-up and aggressive comprehensive risk factor management",
"       </p>",
"      </td>",
"      <td>",
"       Yes, if asymptomatic.",
"      </td>",
"      <td rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       No if:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Abnormal ETT&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Ischemic changes on ECG&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Functional incapacitation by one of conditions.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CHD risk equivalent is defined as presence of diabetes mellitus, peripheral vascular disease, or Framingham risk score predicting a 20 percent CHD event risk over the next 10 years.",
"     <br>",
"      &bull; Abnormal ETT is defined by an inability to exceed 6 METS (beyond completion of Stage II, or 6 minutes) on a standard Bruce protocol or the presence of ischemic symptoms and/or signs (eg, characteristic angina pain or 1 mm ST depression or elevation in 2 or more leads), inappropriate SBP and/or heart rate responses (eg, inability in the maximal heart rate to meet or exceed 85 percent of age-predicted maximal heart rate), or ventricular dysrhthymia.",
"      <br>",
"       &Delta; Ischemic ECG changes are defined by the presence of new 1 mm ST-segment elevation or depression and/or marked T wave abnormality.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with SVT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lone atrial fibrillation",
"      </td>",
"      <td class=\"sublist_other\">",
"       Good prognosis and low risk for stroke",
"      </td>",
"      <td class=\"sublist_other\">",
"       Yes",
"      </td>",
"      <td class=\"sublist_other\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" rowspan=\"4\">",
"       Atrial fibrillation as cause of or a risk for stroke",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"4\">",
"       Risk for stroke decreased by anticoagulation",
"      </td>",
"      <td class=\"sublist_other\">",
"       Yes if:",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulated adequately for at least 1 month",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulation monitored by at least monthly INR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Rate/rhythm control deemed adequate (recommend assessment by cardiologist)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" rowspan=\"5\">",
"       Atrial fibrillation following thoracic surgery",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"5\">",
"       Good prognosis and duration usually limited",
"      </td>",
"      <td class=\"sublist_other\">",
"       In atrial fibrillation at time of return to work",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist_other\">",
"       Yes if:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulated adequately for at least 1 month",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulation monitored by at least monthly INR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Rate/rhythm control deemed adequate (recommend assessment by cardiologist)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Atrial flutter",
"      </td>",
"      <td rowspan=\"5\">",
"       Same as for atrial fibrillation",
"      </td>",
"      <td>",
"       Same as for atrial fibrillation",
"      </td>",
"      <td>",
"       Same as for atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Isthmus ablation performed and at least 1 month after procedure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Arrhythmia successfully treated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Multifocal atrial tachycardia",
"      </td>",
"      <td rowspan=\"6\">",
"       Often associated with comorbidities, such as lung disease, that may impair prognosis",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Unless associated condition is disqualifying",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"2\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Symptoms controlled and secondary cause is not exclusionary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <p>",
"        Atrioventricular Nodal Reentrant Tachycardia (AVNRT)",
"       </p>",
"       <p>",
"        Atrioventricular Reentrant Tachycardia (AVRT) and Wolff-Parkinson-White (WPW) syndrome",
"       </p>",
"       <p>",
"        Atrial tachycardia",
"       </p>",
"       <p>",
"        Junctional tachycardia",
"       </p>",
"      </td>",
"      <td rowspan=\"6\">",
"       <p>",
"        Prognosis generally excellent, but may rarely have syncope or symptoms of cerebral hypoperfusion",
"       </p>",
"       <p>",
"        For those with WPW, preexcitation presents risk for death or syncope if atrial fibrillation develops",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       No if:",
"      </td>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Symptomatic or",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - WPW with atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend consultation with cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Treated and asymptomatic for at least 1 month and assessed and cleared by expert in cardiac arrhythmias",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with ventricular arrhythmias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Coronary Heart Disease (CHD)",
"      </td>",
"      <td>",
"       Sustained VT: poor prognosis and high risk",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NSVT, LVEF &lt;0.40: unfavorable prognosis",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       NSVT, LVEF &ge;0.40: generally considered to have good prognosis",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Cardiology examination required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after drug or other therapy is successful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by cardiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Dilated cardiomyopathy",
"      </td>",
"      <td>",
"       NSVT (LVEF &le;0.40)",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sustained VT, any LVEF",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syncope/near syncope, any LVEF: high risk",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypertrophic cardiomyopathy",
"      </td>",
"      <td>",
"       Variable but uncertain prognosis",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Right ventricular outflow VT",
"      </td>",
"      <td rowspan=\"6\">",
"       Favorable prognosis and low risk for syncope",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yes, if asymptomatic",
"      </td>",
"      <td>",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend evaluation by cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Evaluation by cardiologist required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after drug or other therapy successful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Idiopathic left ventricular VT",
"      </td>",
"      <td rowspan=\"5\">",
"       Favorable prognosis and low risk for syncope",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yes, if asymptomatic",
"      </td>",
"      <td>",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend evaluation by cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Evaluation by cardiologist required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after successful drug therapy or ablation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Long QT interval syndrome",
"      </td>",
"      <td>",
"       High risk for ventricular arrhythmic death",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brugada syndrome",
"      </td>",
"      <td>",
"       High risk for ventricular arrhythmic death",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EF: ejection fraction; LV: left ventricular; NSVT: nonsustained ventricular tachycardia; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with bundle branch blocks",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"8\">",
"       <p>",
"        Bundle branch block",
"       </p>",
"       <p>",
"        Axis deviation",
"       </p>",
"      </td>",
"      <td rowspan=\"8\">",
"       Progression of disease in the conduction system can lead to third degree heart block with total loss of electrical connection between the atria and ventricles causing syncope or sudden death",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       Every 2 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Depends on risk from underlying heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes, if:",
"      </td>",
"      <td rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Treated for symptomatic disease (see pacemaker)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       No disqualifying heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by cardiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with pacemakers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic/functional",
"       </td>",
"       <td class=\"subtitle1\">",
"        Certification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Re-certification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Sinus node dysfunction",
"       </td>",
"       <td rowspan=\"5\">",
"        Variable long-term prognosis depending on underlying disease, but cerebral hypoperfusion corrected by support of heart rate by pacemaker",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Documented pacemaker checks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - 1 month after pacemaker implantation and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Documented correct function by pacemaker center and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Underlying disease is not disqualifying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Atrioventricular (AV) block",
"       </td>",
"       <td rowspan=\"5\">",
"        Variable long-term prognosis depending on underlying disease, but cerebral hypoperfusion corrected by support of heart rate by pacemaker",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Documented pacemaker checks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - 1 month after pacemaker implantation and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Documented correct function by pacemaker center and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Underlying disease is not disqualifying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Neurocardiogenic syncope",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Excellent long-term survival prognosis but there is risk for syncope that may be due to cardioinhibitory (slowing heart rate) or vasodepressor (drop in blood pressure) components, or both",
"        </p>",
"        <p>",
"         Pacemaker will affect only cardioinhibitory component, but will lessen effect of vasodepressor component",
"        </p>",
"       </td>",
"       <td>",
"        No, with symptoms",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Documented pacemaker checks",
"        </p>",
"        <p>",
"         Absence of symptom recurrence",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - 3 months* after pacemaker implantation and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Documented correct function by pacemaker center and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Absence of symptom recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Hypersensitive carotid sinus with syncope",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Excellent long-term survival prognosis but there is risk for syncope that may be due to cardioinhibitory (slowing heart rate) or vasodepressor (drop in blood pressure) components, or both",
"        </p>",
"        <p>",
"         Pacemaker will affect only cardioinhibitory component, but will lessen effect of vasodepressor component",
"        </p>",
"       </td>",
"       <td>",
"        No, with symptoms",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Yes if:",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Annual",
"        </p>",
"        <p>",
"         Documented regular pacemaker checks and",
"        </p>",
"        <p>",
"         Absence of symptom recurrence",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - 3 months* after pacemaker implantation and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Documented correct function by pacemaker center and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Absence of symptom recurrence",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Three months recommended due to possible vasodepressor component of syndrome not necessarily treated by pacing.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with implantable defibrillators",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary prevention",
"      </td>",
"      <td>",
"       Patient has high risk for death and sudden incapacitation",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secondary prevention",
"      </td>",
"      <td>",
"       Patient demonstrated to have high risk for death and sudden incapacitation",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5986=[""].join("\n");
var outline_f5_54_5986=null;
var title_f5_54_5987="Neonatal femur fracture";
var content_f5_54_5987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Neonatal femur fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) This infant had a birth-related left femoral fracture. Panel B) An anteroposterior splint was used but ended at the fracture site, only increasing the angulation. Panel C) A Pavlik harness reduced the fracture by flexing the distal fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5987=[""].join("\n");
var outline_f5_54_5987=null;
var title_f5_54_5988="Calcipotriol (calcipotriene): Drug information";
var content_f5_54_5988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcipotriol (calcipotriene): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/0/23556?source=see_link\">",
"    see \"Calcipotriol (calcipotriene): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcitrene&trade;;",
"     </li>",
"     <li>",
"      Dovonex&reg;;",
"     </li>",
"     <li>",
"      Sorilux&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5383147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dovonex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Apply a thin film to the affected skin twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Foam: Apply a thin film to the affected skin or scalp twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Apply a thin film to the affected skin once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Apply to the affected scalp twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sorilux&trade;: 0.005% (60 g, 120 g) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.005% (60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dovonex&reg;: 0.005% (60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcitrene&trade;: 0.005% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.005% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dovonex&reg;: 0.005% (60 mL) [contains isopropyl alcohol 51% v/v]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes aerosol foam",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F639165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     For external use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cream, foam, ointment: Apply to affected skin; rub in gently and completely. Wash hands thoroughly before and after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Foam, solution: Prior to using, comb hair to remove debris; apply only to scalp lesions. Rub in gently and completely.. Avoid contact with face and eyes (rinse thoroughly with water if contact occurs). Wash hands thoroughly before and after use. Foam should be applied when hair is dry.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of plaque psoriasis of the body (cream, foam, ointment) or of the scalp (foam, solution)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Frequency may vary with site of application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Burning, itching, rash, skin irritation, stinging, tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Application site pain, dermatitis, dry skin, erythema, peeling, pruritus, worsening of psoriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Hypercalcemia, hyperpigmentation, folliculitis, skin atrophy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcipotriene or any component of the formulation; patients with demonstrated hypercalcemia or evidence of vitamin D toxicity; use on the face (cream, ointment); patients with acute psoriatic eruptions (scalp solution)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: May cause transient increases in serum calcium (reversible); if hypercalcemia occurs, discontinue treatment until levels return to normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue use if irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; severity of skin-related adverse reactions may be increased compared to younger adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Foam, solution: Flammable; keep the foam and the solution away from fire, flame, or smoking during and immediately following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; not for ophthalmic, oral, or intravaginal use. Avoid or limit excessive exposure to natural or artificial sunlight, or phototherapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5633323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. There are no adequate or well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F144066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F144058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Calcipotriene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 g): $423.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Dovonex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 g): $516.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Sorilux External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 g): $440.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Calcipotriene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 g): $361.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Calcitrene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 g): $382.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcipotriene External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (60 mL): $339.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2841592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5383708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aofuqing (CL);",
"     </li>",
"     <li>",
"      Calskin (TW);",
"     </li>",
"     <li>",
"      Cipotriol (HK);",
"     </li>",
"     <li>",
"      Daivonex (AR, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GT, GY, HK, HN, ID, IL, IN, IT, JM, KP, MX, MY, NL, NO, NZ, PA, PH, PK, PL, PR, PT, RU, SE, SR, SV, TH, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Dovonex (EG, GB, GR, IE, JP, ZA);",
"     </li>",
"     <li>",
"      Kolkatriol (ID);",
"     </li>",
"     <li>",
"      Kolkatriol F (ID);",
"     </li>",
"     <li>",
"      Psorcutan (AT, DE, PL, TR);",
"     </li>",
"     <li>",
"      Scepos (TW);",
"     </li>",
"     <li>",
"      Xamiol (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic vitamin D",
"     <sub>",
"      3",
"     </sub>",
"     analog which regulates skin cell production and proliferation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F639161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Improvement begins after 2 weeks; marked improvement seen after 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: When applied to psoriasis plaques: Cream, foam: Undetermined; Ointment: ~6%; Solution: &lt;1%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Metabolism: Converted in the skin to inactive metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ashcroft DM, Po AL, Williams HC, et al, \"Systematic Review of Comparative Efficacy and Tolerability of Calcipotriol in Treating Chronic Plaque Psoriasis,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2000, 320(7240):963-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/54/5988/abstract-text/10753146/pubmed\" id=\"10753146\" target=\"_blank\">",
"        10753146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9181 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-93F80B87AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5988=[""].join("\n");
var outline_f5_54_5988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144061\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5383147\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144076\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144062\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144063\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144054\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639165\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144074\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144057\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144045\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298926\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144049\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144050\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5633323\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144066\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144058\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2841592\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5383708\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144044\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F639161\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/0/23556?source=related_link\">",
"      Calcipotriol (calcipotriene): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5989="Acetaminophen, dextromethorphan, and doxylamine: Patient drug information";
var content_f5_54_5989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen, dextromethorphan, and doxylamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35254?source=see_link\">",
"     see \"Acetaminophen, dextromethorphan, and doxylamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7676299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      All-Nite Multi-Symptom Cold/Flu Relief [OTC];",
"     </li>",
"     <li>",
"      Night Time Multi-Symptom Cold/Flu Relief [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cold &amp; Cough Nighttime [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cough &amp; Sore Throat Nighttime [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cold &amp; Flu Nighttime Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; NyQuil&reg; Cold &amp; Flu Multi-Symptom [OTC] [DSC];",
"     </li>",
"     <li>",
"      Vicks&reg; NyQuil&reg; Cold &amp; Flu Nighttime Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease cold signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, dextromethorphan, doxylamine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt diet (this drug has salt), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12078 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5989=[""].join("\n");
var outline_f5_54_5989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026424\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026426\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026425\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026430\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026431\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026433\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026428\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026429\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026434\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026435\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35254?source=related_link\">",
"      Acetaminophen, dextromethorphan, and doxylamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5990="Estradiol and norgestimate: Patient drug information";
var content_f5_54_5990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estradiol and norgestimate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/51/29495?source=see_link\">",
"     see \"Estradiol and norgestimate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prefest&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off soft, brittle bones (osteoporosis) in women after change of life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estradiol, norgestimate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, kidney failure, liver disease, liver tumor, poor adrenal function, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you do not have a uterus and are using this drug to treat signs of stopping periods (menopause) or to put off soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696938",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have a history of breast cancer or a strong family history of breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of caffeine (for example, tea, coffee, cola) and chocolate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug works best when used with calcium/vitamin D and weight-bearing workouts like walking or PT (physical therapy).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12435 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5990=[""].join("\n");
var outline_f5_54_5990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167248\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027416\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027418\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027417\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027422\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027423\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027425\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027420\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027421\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027426\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027427\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/51/29495?source=related_link\">",
"      Estradiol and norgestimate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5991="NI secretory endometrium";
var content_f5_54_5991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secretory endometrium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note tortuous glands, subnuclear vacuoles, without glandular crowding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell S Vang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5991=[""].join("\n");
var outline_f5_54_5991=null;
var title_f5_54_5992="Celecoxib: Pediatric drug information";
var content_f5_54_5992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Celecoxib: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"    see \"Celecoxib: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40949?source=see_link\">",
"    see \"Celecoxib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeleBREX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celebrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1004282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1004317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"      see \"Celecoxib: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 years: JIA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;10 kg to &le;25 kg: 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;25 kg: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute pain or primary dysmenorrhea: Initial dose: 400 mg, followed by an additional 200 mg if needed on day 1; maintenance dose: 200 mg twice daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ankylosing spondylitis: 200 mg/day as a single dose or in divided doses twice daily; if no effect after 6 weeks, may increase to 400 mg/day. If no response following 6 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Familial adenomatous polyposis: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Osteoarthritis: 200 mg/day as a single dose or in divided doses twice daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis: 100-200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No specific dosage adjustment is recommended; not recommended in patients with severe renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment: AUC is increased by 40%; monitor closely; reduce dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hepatic impatient (Child-Pugh Class B): AUC is increased by 180%; monitor closely; decrease daily recommended dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh Class C): Has not been studied; use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in poor metabolizers of CYP2C9 substrates",
"     </b>",
"     : Use with caution in patients who are known or suspected poor metabolizers of cytochrome P450 isoenzyme 2C9 substrates. In poor metabolizers, consider initiation at 50% of the lowest recommended dose. Consider alternate therapy in JIA patients who are poor metabolizers.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeleBREX&reg;: 50 mg, 100 mg, 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088567.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088567.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5184079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower doses (up to 200 mg twice daily) may be administered without regard to meals (may administer with food to reduce GI upset); larger doses should be administered with food to improve absorption. Do not administer with antacids. Capsules may be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce; the contents of the capsule sprinkled onto applesauce may be stored under refrigeration for up to 6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1004306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1004283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of signs and symptoms of osteoarthritis, adult rheumatoid arthritis, juvenile idiopathic arthritis (JIA) (FDA approved in ages &ge;2 years), and ankylosing spondylitis; management of acute pain; treatment of primary dysmenorrhea; to reduce the number of intestinal polyps in familial adenomatous polyposis (FAP).",
"     <b>",
"      Note:",
"     </b>",
"     Celecoxib does not affect platelet aggregation and thus, should not be used as a substitute for aspirin for cardiovascular prophylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CeleBREX&reg; may be confused with CeleXA&reg;, Cerebyx&reg;, Cervarix&reg;, Clarinex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F148443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, aortic valve incompetence, chest pain, coronary artery disorder, edema, facial edema, hypertension (aggravated), MI, palpitation, peripheral edema, sinus bradycardia, tachycardia, ventricular hypertrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fatigue, fever, headache,  hypoesthesia, insomnia, migraine, nervousness,  pain, somnolence,  vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, dermatitis, dry skin, photosensitivity, pruritus, rash (erythematous), rash (including maculopapular), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, hypercholesterolemia, hyperglycemia, hypokalemia, ovarian cyst, testosterone decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, diverticulitis, dyspepsia, dysphagia, eructation, esophagitis, flatulence, gastritis, gastroenteritis, gastroesophageal reflux, gastrointestinal ulcer,  hemorrhoids, hiatal hernia, melena, nausea,  stomatitis, tenesmus, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, dysuria, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, thrombocythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthrosis, back pain, CPK increased, hypertonia, leg cramps, myalgia, paresthesia, synovitis, tendonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival hemorrhage, vitreous floaters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, BUN increased, creatinine increased, hematuria, nonprotein nitrogen increased, renal calculi",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, bronchospasm, cough, dyspnea, epistaxis, laryngitis, nasopharyngitis, pharyngitis, pneumonia, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, allergy aggravated, cyst, diaphoresis, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, agranulocytosis, anaphylactoid reactions, angioedema, anosmia, aplastic anemia, aseptic meningitis, cerebrovascular accident, CHF, cholelithiasis, colitis, DVT, erythema multiforme, esophageal perforation, exfoliative dermatitis, gangrene, gastrointestinal bleeding, hepatic failure, hepatic necrosis, hepatitis (including fulminant), hypoglycemia, hyponatremia, ileus, interstitial nephritis, intestinal obstruction, intestinal perforation, intracranial hemorrhage, jaundice, leukopenia, pancreatitis, pancytopenia, pulmonary embolism, renal papillary necrosis, sepsis, Stevens-Johnson syndrome, sudden death, suicide, syncope, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, vasculitis, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1004290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to celecoxib, any component, sulfonamides (celecoxib is a sulfonamide), aspirin, or other NSAIDs; patients with the &ldquo;aspirin triad&rdquo; [asthma, rhinitis (with or without nasal polyps) and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass surgery (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6269913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with mild or moderate hepatic impairment; use in patients with severe hepatic impairment (Child-Pugh Class C) is not recommended. Closely monitor patients with abnormal LFTs; severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, jaundice, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with asthma; asthmatic patients may have aspirin-sensitive asthma which may be associated with severe and potentially fatal bronchospasm when aspirin or NSAIDs are administered. Anemia may sometimes occur; monitor hemoglobin and hematocrit in patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in pediatric patients with systemic-onset JIA; serious adverse reactions, including disseminated intravascular coagulation, may occur. Celecoxib is FDA-approved for use in children with JIA who are &ge;2 years of age and &ge;10 kg; safety and efficacy of use in children with JIA for &gt;6 months have not been evaluated; long-term cardiovascular toxicity in children has not been studied. Consider alternate therapy in JIA patients who are CYP2C9 poor metabolizers (see next paragraph). Safety and efficacy have not been established for use in children for indications other than JIA.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution and consider dosage reduction in patients who are known or suspected poor metabolizers of cytochrome P450 isoenzyme 2C9 substrates; these patients may have unusually high plasma levels due to reduced clearance. Consider alternate therapy in JIA patients who are identified to be CYP2C9 poor metabolizers. In a small pediatric study (n=4), the AUC of celecoxib was ~10 times higher in a child who was homozygous for CYP2C9*3, compared to children who were homozygous for the *1 allele (n=2) or who had the CYP2C9*1/*2 genotype; further studies are needed to determine if carriers of the CYP2C9*3 allele are at increased risk for cardiovascular toxicity or dose-related adverse effects of celecoxib, especially with long-term, high-dose use of the drug (Stempak, 2005). Adult subjects who were homozygous for CYP2C9*3/*3 displayed celecoxib serum concentrations 3-7 times higher than subjects with CYP2C9*1/*1 or CYP2C9*1/*3 genotypes. The frequency of CYP2C9*3/*3 genotype is estimated to be 0.3% to 1% in various ethnic groups. Celecoxib should not be used as a substitute for corticosteroid therapy or to treat corticosteroid insufficiency. Avoid concomitant use of celecoxib and other NSAIDs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1004291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis; discontinue use at first sign of skin rash or any other sign of hypersensitivity reaction. Avoid use of NSAIDs in late pregnancy (&ge;30 weeks gestation) as they may cause premature closure of the ductus arteriosus. When used for the treatment of FAP, routine monitoring and care should be continued (ie, do",
"     <b>",
"      not",
"     </b>",
"     decrease frequency of routine endoscopic examinations or delay prophylactic colectomy or other FAP-related surgeries; use of celecoxib has",
"     <b>",
"      not",
"     </b>",
"     been shown to decrease risk of GI cancer in patients with FAP).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F148430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor). Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: NSAID (COX-2 Inhibitor) may enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (COX-2 Inhibitor) may enhance the anticoagulant effect of Vitamin K Antagonists. NSAID (COX-2 Inhibitor) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1004305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: A high-fat meal delays the time to peak concentrations by 1-2 hours and increases AUC by 10% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pediatric cancer patients: In a nonrandomized, noncrossover study, a high-fat meal or snack increased AUC by 60% (single-dose) and increased AUC by 75% at steady-state (Stempak, 2005a).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (prior to 30 weeks gestation)/D (&ge;30 weeks gestation) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F148389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal studies; therefore, celecoxib is classified as pregnancy category C. Celecoxib is a NSAID that primarily inhibits COX-2 whereas other currently available NSAIDs are nonselective for COX-1 and COX-2. The effects of this selective inhibition to the fetus have not been well studied and limited information is available specific to celecoxib. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because it may cause premature closure of the ductus arteriosus, the use of celecoxib is not recommended &ge;30 weeks gestation. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including celecoxib. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1004323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC; blood chemistry profile; occult blood loss; periodic liver function tests; renal function (urine output, serum BUN and creatinine); monitor efficacy (eg, in arthritic conditions: Pain, range of motion, grip strength, mobility), inflammation; observe for weight gain, edema; observe for bleeding, bruising; evaluate GI effects (abdominal pain, bleeding, dyspepsia); blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1004308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase-2 (COX-2), which results in decreased formation of prostaglandin precursors. Celecoxib does not inhibit cyclooxygenase-1 (COX-1) at therapeutic concentrations. Celecoxib does not affect platelet aggregation. In FAP, celecoxib reduces the number of colorectal polyps.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1004310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Prolonged due to low solubility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes into breast milk; V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children (steady-state): 8.3 &plusmn; 5.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: ~400 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~97%; primarily to albumin; binds to alpha 1-acid glycoprotein to a lesser extent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP2C9; forms 3 inactive metabolites (a primary alcohol, corresponding carboxylic acid, and its glucuronide conjugate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Absolute: Unknown.",
"     <b>",
"      Note:",
"     </b>",
"     Meta-analysis suggests the AUC is 40% higher in Blacks compared to Caucasians (clinical significance unknown)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children (steady-state): 6 &plusmn; 2.7 hours (range: 3-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: ~11 hours (fasted)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Median: 3 hours (range: 3-6.2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination:  Feces (57% as metabolites, &lt;3% as unchanged drug); urine (27% as metabolites, &lt;3% as unchanged drug); primary metabolites in feces and urine: Carboxylic acid metabolite (73% of dose); low amounts of glucuronide metabolite appear in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1004326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40949?source=see_link\">",
"      see \"Celecoxib: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain; it is unclear whether celecoxib has rates of these events which are similar to nonselective NSAIDs. Notify physician before use if you have hypertension; heart failure; heart, liver, or kidney disease; history of stomach ulcers or bleeding in stomach or intestines; asthma; aspirin-sensitive asthma; or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of celecoxib.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid alcohol, aspirin, and OTC medication unless approved by prescriber. May cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination (avoid driving or engaging in tasks requiring alertness until response to drug is known). Stop taking medication and report immediately stomach pain or cramping; unusual bleeding or bruising (blood in vomitus, stool, or urine); chest pain; shortness of breath; swelling of face or throat; weakness of extremities; slurring of speech or skin rash. Report persistent insomnia; unusual fatigue or flu-like symptoms; jaundice; muscle pain, tremors, or weakness; sudden weight gain or edema; changes in hearing (ringing in ears) or vision; changes in urination pattern; or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Knoppert DC, Stempak D, Baruchel S, et al, \"Celecoxib in Human Milk: A Case Report,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):97-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/54/5992/abstract-text/12523466/pubmed\" id=\"12523466\" target=\"_blank\">",
"        12523466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stempak D, Bukaveckas BL, Linder M, et al, \"Cytochrome P450 2C9 Genotype: Impact on Celecoxib Safety and Pharmacokinetics in a Pediatric Patient,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(3):309-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/54/5992/abstract-text/16153401/pubmed\" id=\"16153401\" target=\"_blank\">",
"        16153401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stempak D, Gammon J, Halton J, et al, \"Modulation of Celecoxib Pharmacokinetics by Food in Pediatric Patients,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005a, 77(3):226-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/54/5992/abstract-text/15735617/pubmed\" id=\"15735617\" target=\"_blank\">",
"        15735617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stempak D, Gammon J, Klein J, et al, \"Single-Dose and Steady-State Pharmacokinetics of Celecoxib in Children,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 72(5):490-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/54/5992/abstract-text/12426512/pubmed\" id=\"12426512\" target=\"_blank\">",
"        12426512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12999 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5992=[""].join("\n");
var outline_f5_54_5992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708651\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148404\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148405\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004282\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004317\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148366\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874407\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5184079\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004306\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004283\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148446\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148443\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004290\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6269913\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004291\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148430\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004305\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148377\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148389\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004323\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004308\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004310\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004326\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12999|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=related_link\">",
"      Celecoxib: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40949?source=related_link\">",
"      Celecoxib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5993="Renal manifestations of Henoch-Schnlein purpura (IgA vasculitis)";
var content_f5_54_5993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis (IgAV), is a systemic vasculitis with a prominent cutaneous component. Cutaneous manifestations similar to those of HSP (IgAV) are also seen in two other disorders, mixed",
"    <span class=\"nowrap\">",
"     (IgG/IgM)",
"    </span>",
"    cryoglobulinemia and hypersensitivity vasculitis (which includes what had been called serum sickness) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Skin vasculitis with palpable petechiae or purpura is typically a major finding in these disorders (",
"    <a class=\"graphic graphic_picture graphicRef63367 \" href=\"UTD.htm?32/32/33282\">",
"     picture 1",
"    </a>",
"    ). A general overview of the different vasculitic disorders is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSP (IgAV) is characterized by the tissue deposition of IgA-containing immune complexes [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/1\">",
"     1",
"    </a>",
"    ]. The histologic findings in the kidney are identical to those in IgA nephropathy, suggesting that the two disorders may have a similar pathogenesis. The observation of the simultaneous occurrence of HSP (IgAV) and IgA nephropathy in twins after an adenovirus infection is further evidence in support of a common pathogenesis [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=see_link\">",
"     \"Pathogenesis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgA deposition is prominent in both HSP (IgAV) and IgA nephropathy (",
"    <a class=\"graphic graphic_picture graphicRef69895 \" href=\"UTD.htm?23/2/23599\">",
"     picture 2",
"    </a>",
"    ), but the renal injury may be mediated at least in part by IgG autoantibodies directed against mesangial cell antigens [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The course of the renal disease and circulating antibody titers are roughly parallel, and these autoantibodies do not appear to be present in patients with HSP (IgAV) who do not have renal involvement [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSP (IgAV) occurs more often in children than in adults, but renal involvement is more likely to occur and to be more severe, in older children and in adults, prompting more aggressive therapy [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. The renal manifestations of HSP (IgAV), including prognosis and treatment, will be reviewed here. The clinical features, pathogenesis, diagnosis and management of HSP (IgAV) in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=see_link\">",
"     \"Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic tetrad of Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis (IgAV), is rash, arthralgias, abdominal pain, and renal disease, which can develop in any order and at any time over a period of several days to several weeks [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/6,7,10,11\">",
"     6,7,10,11",
"    </a>",
"    ]. Renal involvement is typically noted within a few days to one month after the onset of systemic symptoms, but is not predictably related to the severity of extrarenal involvement. In a prospective study of 223 children under 16 years of age, the presence of abdominal pain but not melena or joint symptoms conferred a significant increase in the risk for nephritis (odds ratio 2.1, 95% CI 1.1-3.7) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urinalysis in patients with HSP (IgAV) nephritis reveals an active sediment characterized by microscopic or macroscopic hematuria with or without red cell and other cellular casts or proteinuria. There is a general correlation between the severity of the renal manifestations and the findings on renal biopsy [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. Patients with only asymptomatic hematuria, for example, usually have only focal mesangial proliferation, whereas patients with proteinuria have more marked cellular proliferation and, if nephrotic, may have crescent formation [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Patients with repeated attacks of purpura or macroscopic hematuria often have exacerbation of renal symptoms and biopsy-confirmed worsening of glomerular lesions.",
"   </p>",
"   <p>",
"    The renal biopsy findings in HSP (IgAV) nephritis are essentially indistinguishable from those in IgA nephropathy, which can be idiopathic or secondary to a number of conditions. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSP (IgAV) nephritis is generally mild in children (particularly young children), while adults are more likely to develop moderate to severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44949847\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective cohort studies found that 20 to 54 percent of children with HSP (IgAV) had some degree of early renal involvement [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/9,11,19-23\">",
"     9,11,19-23",
"    </a>",
"    ]. The risk is greater in older children. In a study cited above, for example, age greater than eight years conferred a 2.7-fold increase in the risk of nephritis [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data on the frequency and time of presentation of renal disease were provided by a systemic review of 12 studies of 1133 children with HSP (IgAV) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/22\">",
"     22",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proteinuria were present in 387 (34 percent).",
"     </li>",
"     <li>",
"      Among the patients with renal disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      79 percent had isolated hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      non-nephrotic range proteinuria.",
"     </li>",
"     <li>",
"      21 percent had nephrotic range proteinuria with or without edema or hypoalbuminemia, an elevated blood urea nitrogen or serum creatinine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. As mentioned below, these patients had a worse renal prognosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of renal manifestations occurred within four weeks in 84 percent, within six weeks in 91 percent, and within six months in 97 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a retrospective review of 261 children with HSP (IgAV) published after the meta-analysis [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/20\">",
"     20",
"    </a>",
"    ]. Renal involvement was detected in 52 (20 percent) within four weeks of diagnosis. The following findings were noted in the patients with renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microscopic hematuria &mdash; 71 percent",
"     </li>",
"     <li>",
"      Macroscopic (gross) hematuria &mdash; 10 percent",
"     </li>",
"     <li>",
"      Proteinuria &mdash; 48 percent; among the 30 patients with proteinuria, 28 also had hematuria and 2 had isolated proteinuria",
"     </li>",
"     <li>",
"      Nephrotic syndrome &mdash; 4 percent (two patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44949855\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with HSP (IgAV) generally have similar clinical manifestations as children with a few exceptions, one of which is an increased risk of progressive renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Clinical manifestations in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/7,8,24,25\">",
"     7,8,24,25",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/26\">",
"     26",
"    </a>",
"    ] have found that renal involvement in HSP (IgAV) tends to be more severe in adults than in children as manifested by a higher frequency of nephrotic syndrome, hypertension, and an elevated serum creatinine [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/7,8,24,25\">",
"     7,8,24,25",
"    </a>",
"    ]. This was best illustrated in a retrospective review of 250 adults (mean age 50 years) with HSP (IgAV) nephritis who underwent renal biopsy [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/25\">",
"     25",
"    </a>",
"    ]. Within four months of presentation, 32 percent had renal insufficiency (creatinine clearance less than 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    that was almost always associated with hematuria (93 percent) and proteinuria (99 percent).",
"   </p>",
"   <p>",
"    Reported rates of end-stage renal disease in adults range from 10 to 30 percent at 15 years [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/8,25,27-30\">",
"     8,25,27-30",
"    </a>",
"    ]. At a median follow-up of almost 15 years in the above study of 250 adults, 11 percent had reached end-stage renal disease, 13 percent had a creatinine clearance less than 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    14 percent had a creatinine clearance between 30 and 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and 50 percent had hematuria (most with proteinuria) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/25\">",
"     25",
"    </a>",
"    ]. Clinical remission, defined as a normal serum creatinine and the absence of hematuria and proteinuria, was attained in only 20 percent.",
"   </p>",
"   <p>",
"    However, there are number of factors other than the severity of HSP (IgAV) nephritis that could have contributed to the high rate of adverse renal outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline values prior to the onset of HSP (IgAV) nephritis were not given and older patients could have an underlying chronic kidney disease such as nephrosclerosis. The findings on renal biopsy are consistent with this concern. Adverse renal predictors on multivariate analysis included a serum creatinine above 120",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (1.35",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      proteinuria greater than 1",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and, on renal biopsy, glomeruli with fibrinoid necrosis (a sign of active disease) or signs of chronic disease such as interstitial fibrosis involving more than 10 percent of the interstitium, and glomerulosclerosis in more than 20 percent of glomeruli. In addition, most of the patients who had a creatinine clearance below 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      within four months of presentation were over age 60. Thus, the high rate of adverse renal outcomes in this study may not accurately describe the prognosis of HSP (IgAV) nephritis in younger adults.",
"     </li>",
"     <li>",
"      Other factors that could have contributed are the long period of follow-up compared with other studies as well as possible selection bias since all patients had renal disease severe enough to warrant renal biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic tetrad (palpable purpura without thrombocytopenia or coagulopathy,",
"    <span class=\"nowrap\">",
"     arthritis/arthralgia,",
"    </span>",
"    abdominal pain, and renal disease) is virtually pathognomonic of HSP (IgAV) in children. The differential diagnosis includes microscopic polyangiitis, clotting disorders, such as the antiphospholipid syndrome, and sepsis [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Clinical manifestations in children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSP (IgAV) in adults must be distinguished from other systemic autoimmune diseases (such as hypersensitivity vasculitis, cryoglobulinemia, and systemic lupus erythematosus) that can produce similar symptoms. One report of 178 patients with HSP (IgAV) or hypersensitivity vasculitis found that hypersensitivity vasculitis was present with 74 percent accuracy in patients who had",
"    <strong>",
"     no more than two",
"    </strong>",
"    of the following criteria [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Bowel angina",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Age at onset &le;20 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of renal disease and hemoptysis can simulate the presentation of granulomatosis with polyangiitis (Wegener's) or anti-GBM antibody disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HSP (IgAV) nephritis is typically based upon the clinical presentation. Confirmation of the diagnosis of HSP (IgAV) requires evidence of tissue deposition in the skin or kidney of IgA by immunofluorescence microscopy. Biopsy of the skin lesions reveals inflammation of the small blood vessels, called a",
"    <strong>",
"     leukocytoclastic vasculitis",
"    </strong>",
"    , which is most prominent in the postcapillary venules (",
"    <a class=\"graphic graphic_picture graphicRef52548 graphicRef66296 \" href=\"UTD.htm?7/58/8106\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A kidney biopsy can be done to establish the diagnosis, but this invasive procedure is generally reserved for patients in whom the diagnosis is uncertain or who have more severe renal involvement. Light microscopy can show a wide spectrum of glomerular changes, ranging from isolated mesangial proliferation, focal and segmental proliferation, to severe crescentic glomerulonephritis. The diagnostic finding is dominant or co-dominant IgA deposition in the mesangium on immunofluorescence, similar to that seen in IgA nephropathy (",
"    <a class=\"graphic graphic_picture graphicRef69895 \" href=\"UTD.htm?23/2/23599\">",
"     picture 2",
"    </a>",
"    ). In addition, immunofluorescence may reveal IgG, IgM, fibrinogen, C3, and properdin in the glomeruli. By electron microscopy, electron dense deposits are typically found in the mesangial areas occasionally extending out into the peripheral capillary loops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term outcome of renal disease in Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis (IgAV), is favorable in most patients, with complete recovery reported in 94 and 89 percent of children and adults, respectively, at a mean follow-up of approximately 18 months [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/7\">",
"     7",
"    </a>",
"    ]. The following discussion on renal prognosis will be limited to HSP (IgAV) in children. The long-term renal prognosis of HSP (IgAV) nephritis has, in most studies, been worse in adults than in children, a finding that may be due in part to concurrent chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H44949855\">",
"     'Adults'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among children, the manifestations of active HSP (IgAV) usually resolve spontaneously. The renal prognosis is excellent when transient hematuria and proteinuria resolves within several months, a course that is generally associated with only focal glomerular involvement [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/13,15,19\">",
"     13,15,19",
"    </a>",
"    ]. Recurrence (relapse) of HSP (IgAV) is common, occurring in up to one-third of patients, and may be more likely among children with renal involvement [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/11,19,33\">",
"     11,19,33",
"    </a>",
"    ]. Recurrent symptoms and signs, which tend to mimic the original episode (but tend to be less severe,) are normally observed within four months of resolution of the initial symptoms [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/11\">",
"     11",
"    </a>",
"    ]. Recurrent disease may not predict worse long-term outcomes.",
"   </p>",
"   <p>",
"    The long-term prognosis of children with HSP (IgAV) nephritis was evaluated in the systematic review of 12 studies of 1133 children with HSP (IgAV) described above [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/22\">",
"     22",
"    </a>",
"    ]. Long-term renal impairment was defined as nephrotic range proteinuria (with or without edema or hypoalbuminemia), a serum creatinine above the upper level of normal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension. The incidence of long-term renal impairment varied with the clinical findings and with sex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0 percent in patients who presented with a normal urinalysis.",
"     </li>",
"     <li>",
"      1.6 percent in patients with isolated hematuria with or without non-nephrotic proteinuria (79 percent of patients with renal disease).",
"     </li>",
"     <li>",
"      19.5 percent in patients with nephrotic range proteinuria, an elevated serum creatinine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension (21 percent of patients with renal disease). These three predictors are also predictors of a worse prognosis in virtually all causes of glomerular disease.",
"     </li>",
"     <li>",
"      The risk of long-term renal impairment was 2.5 times higher in females than males.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the systematic review reached the following conclusions about monitoring. Children with an initially normal urinalysis should have follow-up urine testing for the first six months since 97 percent of children with HSP (IgAV) who develop renal disease do so within this time period [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/22\">",
"     22",
"    </a>",
"    ]. Children with isolated hematuria with or without non-nephrotic range proteinuria that persists after six months should have periodic monitoring of the serum creatinine as long as the hematuria and proteinuria persist. Children at increased risk should be evaluated by a nephrologist.",
"   </p>",
"   <p>",
"    In addition to these clinical predictors of prognosis, there are also pathologic predictors on renal biopsy. In general, the extent of renal injury parallels the clinical severity of renal disease. The percentage of glomeruli showing crescents seems to be the most important prognostic finding. The following observations were noted in a study of 151 children referred to a major academic center and then followed for one to 18 years [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with crescents involving more than 50 percent of glomeruli, 37 percent progressed to end-stage renal disease and another 18 percent had chronic kidney disease.",
"     </li>",
"     <li>",
"      Among patients who developed end-stage renal disease, 86 percent had crescents affecting more than 50 percent of glomeruli.",
"     </li>",
"     <li>",
"      Few or no crescents were seen on initial biopsy in the 70 percent of patients who recovered or had only minimal urinary abnormalities at latest examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Persistent and progressive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of affected patients have persistent renal manifestations. This was illustrated in a population-based retrospective study of 69 Spanish children followed for a median of seven years; 12 percent had continued hematuria and proteinuria, which was strongly associated with the presence of nephrotic syndrome at diagnosis (odds ratio 23), but none had renal insufficiency [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late deterioration can occur even among patients with initial complete resolution of renal manifestations. This issue was addressed in a series of 78 children followed for 23 years; 17 had worsening kidney function, including seven with initial complete renal recovery [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, 16 of 44 pregnancies among previously affected individuals were complicated by hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria even in the absence of active renal disease.",
"   </p>",
"   <p>",
"    Some children progress to end-stage renal disease and require dialysis, as illustrated in the following reports [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/13-16,25,27,35-37\">",
"     13-16,25,27,35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 88 children followed for a mean of nine years, most (86 percent) had no urinary abnormalities; four had heavy proteinuria, and eight had renal insufficiency, of whom three were on dialysis (3 percent) [",
"      <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 83 children followed for a mean of seven years, 7 percent became dialysis dependent, and 14 and 16 percent had a doubling of serum creatinine and persistent proteinuria, respectively [",
"      <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among adults, reported rates of end-stage renal disease are higher than in children, ranging from 10 to 30 percent at 15 years [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/8,25,27-30\">",
"     8,25,27-30",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 250 adults who were followed for a median of almost 15 years, 11 percent became dialysis-dependent [",
"      <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/25\">",
"       25",
"      </a>",
"      ]. An additional 27 percent had a creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (half were &lt;30",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      Only 20 percent were in clinical remission, while 50 percent had hematuria (mostly with other manifestations), 47 percent had minimal or moderate proteinuria, and 8 percent had nephrotic range proteinuria.",
"     </li>",
"     <li>",
"      In another report of 136 adults who were followed for a mean of 5.5 years, 18 (13 percent) were on dialysis, 25 percent had a doubling of the serum creatinine concentration, and 16 percent had proteinuria with normal serum creatinine [",
"      <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with other disorders, a poor renal prognosis is more common among those with the following disease or biopsy manifestations [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/12-14,27,28\">",
"     12-14,27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrotic syndrome",
"     </li>",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Crescentic glomerulonephritis (&gt;50 percent)",
"     </li>",
"     <li>",
"      Tubulointerstitial fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late progression may be related to persistent active disease as manifested by nephrotic syndrome and hematuria, or to irreversible nephron loss during the acute episode, leading to compensatory hyperfiltration (driven in part by intraglomerular hypertension) and hypertrophy in the remaining glomeruli. Over a period of years, these adaptive changes induce further glomerular injury that is independent of the primary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients receive only supportive therapy with hydration, rest and analgesics. There is suggestive evidence that glucocorticoids enhance the rate of resolution of the arthritis and abdominal pain; however, they do not appear to prevent recurrent disease [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/11\">",
"     11",
"    </a>",
"    ]. The general approach to therapy of HSP (IgAV) is discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=see_link\">",
"     \"Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment of HSP (IgAV) nephritis should be considered only in patients with marked proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired renal function during the acute episode. We recommend obtaining a renal biopsy in this setting, since the severity of the histologic lesions (particularly the degree of crescent formation) appears to be the best indicator of prognosis. Patients with limited evidence of renal involvement such as microscopic hematuria, macroscopic hematuria of short duration, or mild proteinuria, are generally not subjected to renal biopsy and are not given specific therapy but should be followed closely for worsening of proteinuria or impairment of renal function [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence from controlled trials that therapy with conventional doses of glucocorticoids has a beneficial effect in patients with renal involvement [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/6,10,12,39,40\">",
"     6,10,12,39,40",
"    </a>",
"    ]. By comparison, high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    may be beneficial in patients with advanced disease, which is usually defined as crescentic nephritis. In this setting, a regimen consisting of pulse intravenous methylprednisolone (250 to 1000 mg per day for three days) followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months) may be beneficial [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/16,41\">",
"     16,41",
"    </a>",
"    ]. This regimen is primarily aimed at reversing the inflammatory process (such as macrophage infiltration), rather than the IgA deposition itself. One prospective, but uncontrolled, study used this regimen in 38 children presenting with the nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    crescents affecting more than 50 percent of glomeruli [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/16\">",
"     16",
"    </a>",
"    ]. Only four (10 percent) progressed to end-stage renal disease, three of whom had been treated late in the course of their disease. Thus, early therapy may be important to prevent irreversible glomerular injury. Some experts recommend a six-month course of daily or alternate day tapering glucocorticoids for all patients with nephrotic range proteinuria and for those with a decreased GFR and significant histologic damage on their biopsy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    alone or with glucocorticoids does not appear to reduce protein excretion or improve or preserve renal function [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may be beneficial in patients with HSP (IgAV) and severe proteinuria [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, in one observational study, of 29 children who had persistent nephrotic range proteinuria despite oral glucocorticoids, 26 patients (90 percent) achieved complete remission with combined treatment with cyclosporine",
"    <span class=\"nowrap\">",
"     (5mg/kg",
"    </span>",
"    per day with target serum levels of 50 to 150",
"    <span class=\"nowrap\">",
"     mg/ml)",
"    </span>",
"    and ACE inhibitors. Oral glucocorticoids were withdrawn shortly after cyclosporine was initiated and intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    was not used. Two patients had partial remission but persistent hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. One patient developed end-stage renal disease, but was non-compliant with cyclosporine. It is not possible to determine from this study whether the reduction in proteinuria was due to the cyclosporine or ACE inhibitor.",
"   </p>",
"   <p>",
"    Other regimens that have been evaluated in children with crescentic nephritis include glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (19 of 21 children showed improvement in renal function in an uncontrolled study) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/44\">",
"     44",
"    </a>",
"    ] and multidrug regimens such as glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or glucocorticoids, cyclophosphamide,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"      warfarin",
"     </a>",
"     ,",
"    </span>",
"    and dipyridamole [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/39,45-47\">",
"     39,45-47",
"    </a>",
"    ]. However, since spontaneous recovery is often observed in patients with crescent formation, it remains unknown whether these regimens are superior to no or less aggressive therapy.",
"   </p>",
"   <p>",
"    Plasmapheresis has also been used in a number of patients with severe, usually crescentic, disease and rapidly progressive renal failure [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/41,48,49\">",
"     41,48,49",
"    </a>",
"    ]. Its efficacy is uncertain (due in part to concurrent administration of glucocorticoids) and there are potential side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .) However, limited data suggests that plasmapheresis alone may be curative in some patients. As an example, among nine children with crescentic nephritis, plasmapheresis constituted the sole therapy for renal involvement, with glucocorticoids only being used for severe abdominal pain [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/49\">",
"     49",
"    </a>",
"    ]. At follow-up at nearly 10 years, four children had complete recovery and two had only microscopic hematuria. The remaining three children had recurrent proteinuria, with progression to end-stage renal failure in two.",
"   </p>",
"   <p>",
"    Intravenous immune globulin has been tried in a small number of patients with IgA nephropathy or HSP (IgAV) nephritis with heavy proteinuria and a progressive decline in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/50\">",
"     50",
"    </a>",
"    ]. More data are required to confirm benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation can be performed in those patients who progress to end-stage renal disease, although recurrent disease can occur [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Mesangial hypercellularity and IgA deposition in the graft are common, but many cases are subclinical. An early study suggested that clinically evident recurrence occurs in approximately 35 percent of patients at five years with a rate of graft loss due to recurrent disease of 11 percent [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51\">",
"     51",
"    </a>",
"    ]. Other reviews suggest a lower rate of recurrence (2.5 and 11.5 percent at 5 and 10 years in one small series) but still show a relatively high risk of graft loss due to recurrent disease [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. As an example, a retrospective review demonstrated 13.5 percent graft loss due to recurrent HSP (IgAV) in 330 patients [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/56\">",
"     56",
"    </a>",
"    ]. The overall graft survival however, appears to be the same for patients with HSP (IgAV) compared to other renal allograft recipients.",
"   </p>",
"   <p>",
"    The diagnosis of recurrent renal disease is based not only upon the demonstration of mesangial IgA deposits but also clinical features of the disease, since isolated deposits can be seen without any clinical features of HSP (IgAV). It is possible that asymptomatic IgA deposits may have been present in the donor kidney prior to transplantation. Several reports have documented this phenomenon, but the IgA deposits disappeared within weeks after transplantation due presumably to the lack of circulating IgA-containing immune complexes in the recipient [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Thus, persistent deposits presumably reflect recurrent disease.",
"   </p>",
"   <p>",
"    Recurrent glomerular disease, often in association with active extrarenal involvement, can lead to loss of the graft [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51,52,54,59\">",
"     51,52,54,59",
"    </a>",
"    ]. Although one study suggested that this was more likely in patients with aggressive initial disease and relatively rapid progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51\">",
"     51",
"    </a>",
"    ], the association between recurrence and severity of the original disease was not confirmed in a later report [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/54\">",
"     54",
"    </a>",
"    ]. It is recommended by some that transplantation be delayed for 12 to 24 months after the disappearance of purpura [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. However, this approach does not prevent recurrent disease in all patients [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some observations suggest that the risk of recurrent disease may be higher in living-related donors, a finding similar to that seen in IgA nephropathy [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However this observation was not confirmed in the retrospective series of 339 patients that is cited above, in which the rate of recurrence was the same for those who received kidneys from deceased donors versus living related donor (13 versus 14.3, respectively) [",
"    <a class=\"abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (HSP), also termed IgA vasculitis (IgAV), is a systemic vasculitis with a prominent cutaneous component that is characterized by the tissue deposition of IgA-containing immune complexes. The pathogenesis of this disorder may be similar to that of IgA nephropathy, which is associated with identical histologic findings in the kidney. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twenty to 54 percent of children with HSP (IgAV) have renal involvement at initial presentation. Renal disease is more common and is often more severe in adults who may present with nephrotic syndrome, acute kidney injury and hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Renal manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of HSP (IgAV) in children includes microscopic polyangiitis, clotting disorders, such as the antiphospholipid syndrome, and sepsis. The differential diagnosis of HSP (IgAV) in adults includes other systemic autoimmune diseases, such as hypersensitivity vasculitis, cryoglobulinemia, and systemic lupus erythematosus. If hemoptysis is present, microscopic polyangiitis, granulomatosis with polyangiitis (Wegener's), and anti-GBM antibody disease should be considered. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by skin or kidney biopsy. A kidney biopsy is reserved for patients in whom the diagnosis is uncertain or who have more severe renal involvement. A kidney biopsy should be done in patients who have marked proteinuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impaired renal function during the acute episode. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the short-term outcome of renal disease in HSP (IgAV) is favorable in most patients, recurrence of HSP (IgAV) is common. A minority of patients with HSP (IgAV) has persistent renal manifestations, and late deterioration can occur even among patients with initial complete resolution of renal manifestations. Among adults, the reported rates of end-stage renal disease range from 10 to 30 percent at 15 years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      appears to provide no benefit to patients with renal disease due to HSP (IgAV). High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      may provide benefit to patients with crescentic nephritis. Some experts recommend a six-month course of tapering daily or alternate day glucocorticoids for patients with the nephrotic syndrome and those with a reduced GFR. For patients with crescentic glomerulonephritis, pulse intravenous methylprednisolone (250 to 1000 mg per day for three days) followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three months) may be effective. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal transplantation can be performed in those patients who progress to end-stage renal disease, although HSP (IgAV) recurs in a substantial proportion of patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/1\">",
"      Kauffmann RH, Herrmann WA, Me&yuml;er CJ, et al. Circulating IgA-immune complexes in Henoch-Sch&ouml;nlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med 1980; 69:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/2\">",
"      Meadow SR, Scott DG. Berger disease: Henoch-Sch&ouml;nlein syndrome without the rash. J Pediatr 1985; 106:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/3\">",
"      O'Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Sch&ouml;nlein purpura. J Clin Invest 1991; 88:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/4\">",
"      O'Donoghue DJ, Jewkes F, Postlethwaite RJ, Ballardie FW. Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. Clin Sci (Lond) 1992; 83:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/5\">",
"      Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Sch&ouml;nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197.",
"     </a>",
"    </li>",
"    <li>",
"     Meadow SR. Sch&ouml;nlein-Henoch syndrome. In: Pediatric Nephrology, 2nd ed, Edelmann CM (Ed), Little, Brown and Co., Boston 1992. p.1525.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/7\">",
"      Blanco R, Mart&iacute;nez-Taboada VM, Rodr&iacute;guez-Valverde V, et al. Henoch-Sch&ouml;nlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 1997; 40:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/8\">",
"      Kellerman PS. Henoch-Sch&ouml;nlein purpura in adults. Am J Kidney Dis 2006; 48:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/9\">",
"      Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child 2010; 95:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/10\">",
"      Cameron JS. Henoch-Sch&ouml;nlein purpura: clinical presentation. Contrib Nephrol 1984; 40:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/11\">",
"      Saulsbury FT. Henoch-Sch&ouml;nlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/12\">",
"      Austin HA 3rd, Balow JE. Henoch-Sch&ouml;nlein nephritis: prognostic features and the challenge of therapy. Am J Kidney Dis 1983; 2:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/13\">",
"      Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch-Sch&ouml;nlein nephritis in children. Br Med J 1977; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     Habib R, Niaudet P, Levy M. Sch&ouml;nlein-Henoch purpura nephritis and IgA nephropathy. In: Renal Pathology with Clinical and Functional Correlations, Tisher CC, Brenner BM (Eds), Lippincott, Philadelphia 1993. p.472.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/15\">",
"      Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Sch&ouml;nlein nephritis. Lancet 1992; 339:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/16\">",
"      Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Sch&ouml;nlein-Henoch purpura nephritis. Pediatr Nephrol 1998; 12:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/17\">",
"      Yoshikawa N, White RH, Cameron AH. Prognostic significance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol 1981; 16:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/18\">",
"      Halling SF, S&ouml;derberg MP, Berg UB. Henoch Sch&ouml;nlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol 2005; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/19\">",
"      Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/20\">",
"      Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Sch&ouml;nlein purpura: a 10-year clinical study. Pediatr Nephrol 2005; 20:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/21\">",
"      Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Sch&ouml;nlein purpura in an unselected childhood population. Eur J Pediatr 1988; 147:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/22\">",
"      Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/23\">",
"      Rieu P, No&euml;l LH. Henoch-Sch&ouml;nlein nephritis in children and adults. Morphological features and clinicopathological correlations. Ann Med Interne (Paris) 1999; 150:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/24\">",
"      Uppal SS, Hussain MA, Al-Raqum HA, et al. Henoch-Sch&ouml;nlein's purpura in adults versus children/adolescents: A comparative study. Clin Exp Rheumatol 2006; 24:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/25\">",
"      Pillebout E, Thervet E, Hill G, et al. Henoch-Sch&ouml;nlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/26\">",
"      Coppo R, Mazzucco G, Cagnoli L, et al. Long-term prognosis of Henoch-Sch&ouml;nlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Sch&ouml;nlein purpura. Nephrol Dial Transplant 1997; 12:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/27\">",
"      Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Sch&ouml;nlein nephritis in children and adults. Am J Kidney Dis 2006; 47:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/28\">",
"      Shrestha S, Sumingan N, Tan J, et al. Henoch Sch&ouml;nlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM 2006; 99:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/29\">",
"      Fogazzi GB, Pasquali S, Moriggi M, et al. Long-term outcome of Sch&ouml;nlein-Henoch nephritis in the adult. Clin Nephrol 1989; 31:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/30\">",
"      Rauta V, T&ouml;rnroth T, Gr&ouml;nhagen-Riska C. Henoch-Schoenlein nephritis in adults-clinical features and outcomes in Finnish patients. Clin Nephrol 2002; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/31\">",
"      Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated Henoch-Sch&ouml;nlein purpura. Arch Dis Child 2002; 86:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/32\">",
"      Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Sch&ouml;nlein purpura: a comparison between the 2 disorders. J Rheumatol 1992; 19:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/33\">",
"      Levy M, Broyer M, Arsan A, et al. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 1976; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/34\">",
"      Calvi&ntilde;o MC, Llorca J, Garc&iacute;a-Porr&uacute;a C, et al. Henoch-Sch&ouml;nlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 2001; 80:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/35\">",
"      Ronkainen J, Ala-Houhala M, Huttunen NP, et al. Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol 2003; 60:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/36\">",
"      Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Sch&ouml;nlein purpura: a retrospective cohort study. Lancet 2002; 360:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/37\">",
"      Shin JI, Park JM, Kim JH, et al. Factors affecting histological regression of crescentic Henoch-Sch&ouml;nlein nephritis in children. Pediatr Nephrol 2006; 21:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/38\">",
"      Davin JC. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011; 6:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/39\">",
"      Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Sch&ouml;nlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 2004; 19:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/40\">",
"      Pillebout E, Alberti C, Guillevin L, et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch&ouml;nlein Purpura. Kidney Int 2010; 78:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/41\">",
"      Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/42\">",
"      Shin JI, Park JM, Shin YH, et al. Cyclosporin A therapy for severe Henoch-Sch&ouml;nlein nephritis with nephrotic syndrome. Pediatr Nephrol 2005; 20:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/43\">",
"      Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Sch&ouml;nlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 2011; 26:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/44\">",
"      Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol 1998; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/45\">",
"      Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Sch&ouml;nlein nephritis. Pediatr Nephrol 1995; 9:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/46\">",
"      Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N. Multiple combined therapy for severe Henoch-Sch&ouml;nlein nephritis in children. Pediatr Nephrol 1998; 12:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/47\">",
"      Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant 2004; 19:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/48\">",
"      Kauffmann RH, Houwert DA. Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. Clin Nephrol 1981; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/49\">",
"      Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Sch&ouml;nlein purpura nephritis in children. Am J Kidney Dis 1999; 33:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/50\">",
"      Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Sch&ouml;nlein purpura. Ann Intern Med 1994; 120:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/51\">",
"      Meulders Q, Pirson Y, Cosyns JP, et al. Course of Henoch-Sch&ouml;nlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994; 58:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/52\">",
"      Nast CC, Ward HJ, Koyle MA, Cohen AH. Recurrent Henoch-Sch&ouml;nlein purpura following renal transplantation. Am J Kidney Dis 1987; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/53\">",
"      Hasegawa A, Kawamura T, Ito H, et al. Fate of renal grafts with recurrent Henoch-Sch&ouml;nlein purpura nephritis in children. Transplant Proc 1989; 21:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/54\">",
"      Kanaan N, Mourad G, Thervet E, et al. Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis. Clin J Am Soc Nephrol 2011; 6:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/55\">",
"      Ponticelli C, Moroni G, Glassock RJ. Recurrence of secondary glomerular disease after renal transplantation. Clin J Am Soc Nephrol 2011; 6:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/56\">",
"      Samuel JP, Bell CS, Molony DA, Braun MC. Long-term outcome of renal transplantation patients with Henoch-Schonlein purpura. Clin J Am Soc Nephrol 2011; 6:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/57\">",
"      Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/58\">",
"      Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc 1987; 19:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis/abstract/59\">",
"      Baliah T, Kim KH, Anthone S, et al. Recurrence of Henoch-Sch&ouml;nlein purpura glomerulonephritis in transplanted kidneys. Transplantation 1974; 18:343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3107 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5993=[""].join("\n");
var outline_f5_54_5993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44949847\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44949855\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Persistent and progressive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3107|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33282\" title=\"picture 1\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/2/23599\" title=\"picture 2\">",
"      IgA nephropathy IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43333\" title=\"picture 3A\">",
"      Leukocytoclastic vasculitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/37/23126\" title=\"picture 3B\">",
"      Leukocytoclastic vasculitis II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28646?source=related_link\">",
"      Management of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5994="Hydrocephalus";
var content_f5_54_5994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hydrocephalus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Abilash Haridas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Tadanori Tomita, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/54/5994/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/54/5994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus is a disorder in which an excessive amount of cerebrospinal fluid (CSF) accumulates within the cerebral ventricles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subarachnoid spaces, which are dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, hydrocephalus is almost always associated with increased intracranial pressure (ICP). In most cases, this is caused by excess CSF accumulating in the cerebral ventricles due to disturbances of CSF circulation (known as obstructive or non-communicating hydrocephalus). Less often, the CSF accumulates because of impaired absorption (known as communicating hydrocephalus). These types of hydrocephalus will be the focus of this topic review.",
"   </p>",
"   <p>",
"    By contrast, in normal pressure hydrocephalus, the cerebral ventricles are pathologically enlarged, but the ICP is within the normal range. This condition is usually caused by impaired CSF absorption. This type of hydrocephalus is more often seen in adults and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=see_link\">",
"     \"Normal pressure hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These forms of hydrocephalus are distinct from two radiographic findings that include the same word. The term &ldquo;hydrocephalus ex-vacuo&rdquo; refers to dilatation of the ventricles secondary to brain atrophy or loss of brain tissue secondary to an insult; hydrocephalus ex-vacuo is not accompanied by increased ICP. The term &ldquo;external hydrocephalus&rdquo; or &ldquo;benign enlargement of the extra-axial spaces&rdquo; refers to excessive fluid, usually CSF, in the subarachnoid spaces and is associated with familial macrocephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of congenital and infantile hydrocephalus in the United States and Europe has been estimated as 0.5 to 0.8 per 1000 live and still births [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Approximately half of these cases are associated with myelomeningocele (spina bifida), but that proportion varies substantially across different populations. There is substantial familial aggregation for congenital hydrocephalus. In a population-based study of congenital hydrocephalus (not including cases associated with neural tube defects), the recurrence risk ratios for same-sex twins, first-degree relatives, and second-degree relatives were 34.8, 6.2, and 2.2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) is produced primarily by the choroid plexus. It circulates through the ventricular system and then through subarachnoid space, in which it is absorbed into the systemic blood circulation. The flow of CSF is primarily cephalad.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2169815\">",
"    <span class=\"h2\">",
"     CSF production",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF is produced primarily by the choroid plexus, which is responsible for 60 to 80 percent of CSF production. The choroid plexus tissue is located in each cerebral ventricle and consists of villous folds lined by epithelium with a central core of highly vascularized connective tissue. The choroidal epithelial cells produce CSF using active transport dependent upon carbonic anhydrase, which can be blocked by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    (Diamox&reg;), a carbonic anhydrase inhibitor. In addition to the active secretion, there is a diffusion component that is not blocked by acetazolamide.",
"   </p>",
"   <p>",
"    The remainder of the CSF is produced by cerebral tissue, which secretes CSF directly into the extracellular space (there are no lymphatic channels in the central nervous system). This fluid flows through the ependymal layer into the cerebral ventricles or the spinal central canal.",
"   </p>",
"   <p>",
"    CSF production rates are constant in physiological conditions unless extremely high levels of intracranial pressure are reached. Thus, absorption of CSF generally matches the rate of production to accommodate the volume of CSF being formed each day. In adults, the production rate of CSF is approximately 20",
"    <span class=\"nowrap\">",
"     mL/hour,",
"    </span>",
"    which results in complete turnover of the CSF three or four times per day. In newborns and young children, the CSF production rate is proportional to the size of the brain. Estimates of CSF production rates in infants and children are derived from measurements of the hourly output of the CSF from external ventricular drains. These studies suggest that CSF output increases logarithmically with age and body weight, ranging from 0.1 to 26.5",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/9\">",
"     9",
"    </a>",
"    ]. Output increases rapidly in infancy; by the age of two years, output is 64 percent of that at 15 years.",
"   </p>",
"   <p>",
"    The total volume of CSF in infants is approximately 50 mL, compared with 125 to 150 mL in normal adults. In adults, approximately 25 percent of the CSF is within the ventricular system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H2#H2\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Physiology of CSF formation and flow'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     CSF circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CSF originating in the choroid plexus and in cerebral tissue circulates through the ventricular system into the subarachnoid space. The ventricular system is comprised of a pair of lateral ventricles, each of which connects to the midline third ventricle through an interventricular foramen (of Monro) (",
"    <a class=\"graphic graphic_figure graphicRef74410 \" href=\"UTD.htm?38/9/39063\">",
"     figure 1",
"    </a>",
"    ). There are no direct connections between two lateral ventricles because they are separated by a membrane (the septum pellucidum). The third ventricle is connected to a midline fourth ventricle by the cerebral aqueduct (of Sylvius). The CSF exits from the fourth ventricle into the subarachnoid space via three foramen: the paired lateral foramina of Luschka and a midline foramen of Magendie. Focally enlarged areas of subarachnoid spaces known as cisterns are present at the base of the brain. The cisterns in the posterior fossa connect to the subarachnoid spaces over the cerebral convexities through pathways that cross the tentorium. The basal cisterns connect the spinal and intracranial subarachnoid spaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CSF absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF is absorbed into the systemic venous circulation primarily across the arachnoid villi into the venous channels of the major sinuses. The arachnoid villi consist of a cluster of cells that project from the subarachnoid space to the sinus lumen; these are covered by a layer of endothelium with tight junctions that are continuous with the inner layer of the sinuses. This assembly acts as a one-way valve, allowing passive absorption of CSF down a pressure gradient; if the CSF pressure is less than the venous pressure, the arachnoid villi close and do not allow blood to pass into the ventricular system. The rate of absorption is relatively linear over the physiological range. Some CSF absorption also occurs across the ependymal lining of the ventricles and the choroid plexus, as well as from the spinal subarachnoid space to the perineural spaces. Although the CSF absorption via a lymphatic system has been noted in animals, this mechanism has not been established in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus results from an imbalance between the intracranial cerebrospinal fluid (CSF) inflow and outflow. It is caused by obstruction of CSF circulation, by inadequate absorption of CSF, or (rarely) by overproduction of the CSF. Regardless of the cause, the excessive volume of CSF causes increased ventricular pressure and leads to ventricular dilatation.",
"   </p>",
"   <p>",
"    It is increasingly recognized that many cases of hydrocephalus have both obstructive and absorptive components [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ]. This accounts for the variable response to third ventriculostomy for cases of hydrocephalus previously presumed to be purely obstructive, as discussed below. Moreover, the absorptive component of the hydrocephalus and the response to treatment may change over time. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Third ventriculostomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism of hydrocephalus is anatomic or functional obstruction to CSF flow (known as obstructive or non-communicating hydrocephalus). The obstruction occurs at the foramen of Monro, at the aqueduct of Sylvius, or at the fourth ventricle and its outlets. Dilatation of the ventricular system occurs proximal to the obstruction. The ventricle just proximal to the obstruction usually dilates most prominently. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstruction of the aqueduct of Sylvius (aqueductal stenosis) causes dilation of the lateral and third ventricles, while the size of the fourth ventricle remains relatively normal. This is a very common cause of hydrocephalus in infants and children.",
"     </li>",
"     <li>",
"      Obstruction at the body of the lateral ventricle causes dilation of the distal temporal horn and atrium.",
"     </li>",
"     <li>",
"      Obstruction of one foramen of Monro causes dilatation of the lateral ventricle on that side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Impaired absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less commonly, hydrocephalus is caused by impaired absorption of CSF, known as communicating hydrocephalus. This is typically due to inflammation of the subarachnoid villi but also may be caused by impaired CSF absorption. The radiographic hallmark of communicating hydrocephalus is dilation of the entire ventricular system, including the fourth ventricle. Impaired CSF absorption also can occur when cranial venous sinus pressure is elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Excessive production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive production of CSF is a rare cause of hydrocephalus. This condition may occur with a functional choroid plexus papilloma. It leads to enlargement of the entire ventricular system and of the subarachnoid spaces, with a radiographic appearance that is similar to communicating hydrocephalus from other causes. (See",
"    <a class=\"local\" href=\"#H434112\">",
"     'Choroid plexus papilloma or carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of hydrocephalus depends upon the underlying cause, upon how quickly the condition develops, and upon the presence of compensatory mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrocephalus that begins in infancy before fusion of the cranial sutures, if untreated, typically results in marked enlargement of the head and in less destruction of brain tissue, compared with hydrocephalus that develops acutely. This is because the skull expands, partially relieving the intracranial pressure. In addition, the force of the intracranial pressure is distributed over the greater surface area of an enlarged ventricular system, so there is less pressure on the brain parenchyma compared with hydrocephalus that develops in a ventricular system that is not previously enlarged.",
"     </li>",
"     <li>",
"      If hydrocephalus occurs acutely or occurs after fusion of the cranial sutures, the head does not enlarge. This results in significantly increased intracranial pressure and in more rapid destruction of brain tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The progression of ventricular dilatation is usually uneven. The frontal and occipital horns typically enlarge first and to the greatest extent. Their progressive enlargement disrupts the ependymal lining of the ventricles, allowing the cerebrospinal fluid (CSF) to move directly into the brain tissue. This reduces CSF pressure but also leads to edema of the subependymal areas and to progressive involvement of the white matter.",
"   </p>",
"   <p>",
"    As the hydrocephalus progresses, edema and ischemia develop in the periventricular brain tissue, leading to atrophy of the white matter. The gyri become flattened, and the sulci become compressed against the cranium, obliterating the subarachnoid space over the hemispheres. The width of the cerebral mantle may be substantially reduced; gray matter is better preserved than white matter, even in advanced stages. The vascular system is compressed, and the venous pressure in the dural sinuses increases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus can be congenital or acquired. Both categories include a diverse group of conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hydrocephalus can result from central nervous system (CNS) malformations (which include nonsyndromic and syndromic disorders), infection, intraventricular hemorrhage, genetic defects, trauma, and teratogens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"     11",
"    </a>",
"    ]. A rare cause of hydrocephalus is obstruction caused by a congenital CNS tumor, especially if located near the midline. The disorders can be grouped according to the primary pathogenic mechanism (obstructive versus absorptive) (",
"    <a class=\"graphic graphic_table graphicRef82965 \" href=\"UTD.htm?13/26/13741\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Neural tube defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with myelomeningocele have hydrocephalus. The etiology is obstruction of fourth ventricular outflow or flow of CSF through the posterior fossa due to the Chiari II malformation or to an associated aqueductal stenosis. This type of hydrocephalus tends to have both an obstructive component and a communicating component [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Encephalocele is another relatively common neural tube defect, in which the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meninges herniate through a defect in the skull. Up to 50 percent of individuals with occipital encephalocele have associated hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=see_link\">",
"     \"Primary (congenital) encephalocele\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Isolated hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated hydrocephalus is frequently caused by aqueductal stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78793 \" href=\"UTD.htm?9/58/10144\">",
"     image 1",
"    </a>",
"    ). This can be due to congenital narrowing of the aqueduct or can result from inflammation due to intrauterine infection. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Intrauterine infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     X-linked hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common genetic form of congenital hydrocephalus is X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (aqueductal stenosis), which accounts for about 5 percent of cases of congenital hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"     11",
"    </a>",
"    ]. Approximately 50 percent of affected boys have adducted thumbs, which is helpful in making the diagnosis. Some have other CNS abnormalities such as agenesis (or dysgenesis) of the corpus callosum, small brainstem, pachygyria, polymicrogyria, or absence of the pyramidal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder is due to mutations in the gene encoding L1, a neuronal cell adhesion molecule that belongs to the immunoglobulin superfamily and that is essential in neurodevelopment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/13\">",
"     13",
"    </a>",
"    ]. The gene for L1 has been mapped to Xq28. Mutations in L1 also result in other conditions, known as the L1 spectrum, that are characterized by neurologic abnormalities and by mental retardation. These include MASA spectrum (",
"    <strong>",
"     M",
"    </strong>",
"    ental retardation,",
"    <strong>",
"     A",
"    </strong>",
"    phasia,",
"    <strong>",
"     S",
"    </strong>",
"    huffling gait,",
"    <strong>",
"     A",
"    </strong>",
"    dducted thumbs), X-linked spastic paraplegia type 1, and X-linked agenesis of the corpus callosum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     CNS malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS malformations are frequently associated with hydrocephalus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Chiari malformations, which often accompany a neural tube defect, portions of the brainstem and cerebellum are displaced caudally into the cervical spinal canal. This obstructs the flow of CSF in the posterior fossa, leading to hydrocephalus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=see_link\">",
"       \"Chiari malformations\"",
"      </a>",
"      .) The Chiari II malformation seen in spina bifida is acquired and is accompanied by other features on a magnetic resonance imaging (MRI), such as agenesis of corpus callosum low lying torcular herophili, tectal breaking, medullary kinking, and heterotopias (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57510 \" href=\"UTD.htm?39/62/40928\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61496 \" href=\"UTD.htm?38/15/39155\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Dandy-Walker malformation consists of a large posterior fossa cyst that is continuous with the fourth ventricle and defective development of the cerebellum, including partial or complete absence of the vermis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69351 \" href=\"UTD.htm?17/55/18294\">",
"       image 4",
"      </a>",
"      ). Hydrocephalus develops in 70 to 90 percent of patients with Dandy-Walker malformation and is caused by atresia of the foramina of Luschka and Magendie. Dandy-Walker malformation is a heterogeneous disorder. Some patients have a syndromic form with associated congenital anomalies including dysgenesis of the corpus callosum, orofacial deformities, and congenital abnormalities of the heart, genitourinary, and gastrointestinal systems [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/14\">",
"       14",
"      </a>",
"      ]. There is a wide range in neurodevelopmental outcomes, which depend upon the effectiveness of management of hydrocephalus as well as the associated central nervous system abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=see_link&amp;anchor=H9#H9\">",
"       \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\", section on 'Dandy-Walker malformation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A vein of Galen malformation is a rare cause of hydrocephalus. Obstruction results from compression of the aqueduct of Sylvius by the markedly dilated and distorted vein of Galen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79131 \" href=\"UTD.htm?23/46/24290\">",
"       image 5",
"      </a>",
"      ). The hydrocephalus in these patients is primarily caused by arterial pressure in the venous system rather than by compression of the aqueduct. Presentation in the neonatal period typically includes intractable heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=see_link&amp;anchor=H12#H12\">",
"       \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\", section on 'Aneurysm of the vein of Galen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Syndromic forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus can be part of syndromes associated with dysmorphic features and with other congenital abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"     11",
"    </a>",
"    ]. The most frequent cytogenetic disorders associated with hydrocephalus are trisomies 13, 18, 9, and 9p, as well as triploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"     11",
"    </a>",
"    ]. Rare autosomal recessive disorders include Walker-Warburg syndrome, which is also characterized by ocular anomalies, and hydrolethalus syndrome, in which micrognathia and postaxial polydactyly of the hands and preaxial polydactyly of the feet are associated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link&amp;anchor=H1689415#H1689415\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Walker-Warburg syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intrauterine infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine infections such as rubella, cytomegalovirus, toxoplasmosis, lymphocytic choriomeningitis (LCM), and syphilis can result in congenital hydrocephalus. The mechanism is inflammation of the ependymal lining of the ventricular system and the meninges in the subarachnoid space [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"     11",
"    </a>",
"    ]. This may lead to impaired absorption of CSF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to obstruction of CSF flow through the aqueduct or basal cisterns [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434112\">",
"    <span class=\"h3\">",
"     Choroid plexus papilloma or carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A papilloma or carcinoma of the chorioid plexus causes communicating hydrocephalus because of increased CSF secretion. This disorder usually can be identified by MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60156 \" href=\"UTD.htm?14/24/14720\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Acquired hydrocephalus",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20710834\">",
"    <span class=\"h3\">",
"     Infections and tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes of acquired hydrocephalus are CNS infections, such as bacterial meningitis or viral infections including mumps, and tumors, especially posterior fossa medulloblastomas, astrocytomas, and ependymomas. These conditions are associated with obstructed flow of CSF through the ventricular system and with impaired CSF absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20710841\">",
"    <span class=\"h3\">",
"     Posthemorrhagic hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important cause is hemorrhage into the subarachnoid space or, less commonly, into the ventricular system, by ruptured aneurysms, arteriovenous malformations, trauma, or systemic bleeding disorders. The hemorrhage induces an inflammatory response followed by fibrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71951 graphicRef82502 \" href=\"UTD.htm?1/6/1125\">",
"     image 7A-B",
"    </a>",
"    ). The main mechanism for hydrocephalus is impaired absorption of CSF (communicating hydrocephalus), although some obstruction to CSF flow also may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link&amp;anchor=H671769#H671769\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\", section on 'Posthemorrhagic hydrocephalus (PHH)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posthemorrhagic hydrocephalus occurs in approximately 35 percent of preterm infants with intraventricular hemorrhage (IVH). It can be obstructive, communicating, or both and can be transient or sustained, with slow or rapid progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2169911\">",
"    <span class=\"h2\">",
"     Low pressure hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an uncommon entity and is extremely challenging to manage. It is diagnosed when neurological improvement is attained by external ventricular drainage. Patients usually have symptomatic ventriculomegaly and surprisingly low intracranial pressure. This condition may result from tumors, chronic hydrocephalus, subarachnoid hemorrhage, and infections. Management is with low pressure shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of hydrocephalus result from increased intracranial pressure (ICP) and dilatation of the ventricles. The time of presentation depends upon the acuity of the process. If accumulation of excessive cerebrospinal fluid (CSF) is slow, allowing adjustments to occur, the patient may have a long period without symptoms. Rapid progression of ventricular dilatation typically results in early development of symptoms. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Symptoms of hydrocephalus are nonspecific and independent of the etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/17\">",
"     17",
"    </a>",
"    ]. Headache is a prominent symptom. It is caused by distortion of the meninges and blood vessels. The pain often varies in intensity and location and may be intermittent or persistent. Headaches due to increased ICP tend to occur in the early morning and may be associated with nausea and vomiting. They tend to occur in the morning because venous pressure is higher in the recumbent position; this reduces CSF absorption and increases ICP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link&amp;anchor=H1170681824#H1170681824\">",
"     \"Approach to the child with headache\", section on 'Worrisome findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients often have changes in their personality and behavior. These include irritability, obstreperousness, indifference, and loss of interest. The mechanism of the behavior changes is uncertain but is related, in part, to increased ICP. As the hydrocephalus worsens, midbrain and brainstem dysfunction may result in lethargy and drowsiness. Increased ICP in the posterior fossa often leads to nausea, vomiting, and decreased appetite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings are due to the effects of increased ICP. The following signs are often present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs &mdash; Distortion of the brainstem may result in changes in vital signs such as bradycardia, systemic hypertension, and altered respiratory rate.",
"     </li>",
"     <li>",
"      Head &mdash; Effects of hydrocephalus on the head are most obvious in infants who develop hydrocephalus while the cranial sutures are still open.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hydrocephalus is an important cause of macrocephaly in infants. Excessive head growth may be noted on serial measurements of head circumference plotted on growth curves. However, significant dilatation of the ventricles can occur before head growth becomes abnormal. The anterior fontanelle may become full or distended. The sutures feel more widely split due to an enlarging head circumference. There is an abnormal percussion note to the head when the sutures are spread (the &ldquo;cracked pot&rdquo; sound or Macewen&rsquo;s sign) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link\">",
"       \"Etiology and evaluation of macrocephaly in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Young infants may develop frontal bossing, an abnormal skull contour in which the forehead becomes prominent.",
"     </li>",
"     <li>",
"      The scalp veins may appear dilated and prominent. This is sometimes noted by the parents and is mentioned in the history.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial nerves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compression of the third or sixth cranial nerve may result in extraocular muscle pareses leading to diplopia.",
"     </li>",
"     <li>",
"      Pressure on the midbrain may result in impairment of upward gaze. This is known as the setting-sun sign because of the appearance of the sclera visible above the iris (",
"      <a class=\"graphic graphic_picture graphicRef58178 \" href=\"UTD.htm?16/19/16695\">",
"       picture 1",
"      </a>",
"      ), and it may be part of a larger constellation of neuro-ophthalmologic signs known as Parinaud syndrome (",
"      <a class=\"graphic graphic_table graphicRef81227 \" href=\"UTD.htm?11/52/12107\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H9#H9\">",
"       \"Supranuclear disorders of gaze in children\", section on 'Parinaud syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fundus &mdash; Funduscopic examination may reveal papilledema.",
"     </li>",
"     <li>",
"      Spine &mdash; The spine of children should be carefully examined for stigmata suggestive of an acquired Chiari II malformation associated with spinal dysraphism, such as a pit located above the gluteal crease, a palpable lumbar mass (suggestive of lipoma), or skin stigmata of spinal dysraphism (",
"      <a class=\"graphic graphic_table graphicRef76756 \" href=\"UTD.htm?5/3/5179\">",
"       table 3",
"      </a>",
"      ). However, if the pit is located between the upper buttocks in the intergluteal cleft and if the coccyx is palpable, the lesion usually is benign and does not require imaging unless neurological or urinary symptoms develop. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=see_link\">",
"       \"Pathogenesis and types of occult spinal dysraphism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Motor function &mdash; Stretching of the fibers from the motor cortex around the dilated ventricles may result in spasticity of the extremities, especially the legs.",
"     </li>",
"     <li>",
"      Growth and pubertal development &mdash; Accelerated pubertal development and disturbed growth, ans well as fluid and electrolyte homeostasis, may result from pressure of the dilated third ventricle on the hypothalamus [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurological examination of infants and children is described in detail in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link\">",
"     \"Detailed neurologic assessment of infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=see_link\">",
"     \"Neurological examination of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and children with suspected hydrocephalus should also be examined for associated congenital anomalies, including bilateral adducted thumbs (suggestive of X-linked hydrocephalus), ocular anomalies (suggestive of Walker-Warburg syndrome), and other syndromic features. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Syndromic forms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus should be suspected in an infant whose head circumference is enlarged at birth or in whom serial measurements cross percentiles in standard growth curves, indicating excessive head growth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link&amp;anchor=H8#H8\">",
"     \"The pediatric physical examination: General principles and standard measurements\", section on 'Weight, height, head, and chest circumference'",
"    </a>",
"    .) In some cases, the diagnosis is made by antenatal ultrasonography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=see_link\">",
"     \"Ultrasound diagnosis of neural tube defects\"",
"    </a>",
"    .) Hydrocephalus should be considered in children with severe headache and other features suggesting increased intracranial pressure (ICP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link&amp;anchor=H1170681824#H1170681824\">",
"     \"Approach to the child with headache\", section on 'Worrisome findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20710988\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hydrocephalus is confirmed by neuroimaging. In a newborn, ultrasonography is the preferred technique for the initial examination because it is portable and avoids ionizing radiation. Ultrasound is good for imaging the lateral ventricles but does not assess the posterior fossa well; the diagnostic accuracy of ultrasound also depends upon the expertise of the user. As the anterior fontanelle closes, the ultrasound is no longer a useful diagnostic modality. In older infants and children with suspected hydrocephalus, computerized tomography (CT) or magnetic resonance imaging (MRI) should be performed. These imaging studies will also detect associated central nervous system (CNS) malformations or tumors.",
"   </p>",
"   <p>",
"    CT is fast, is reliable, and does not interfere with implanted medical devices. Head CT scanning usually can be accomplished without sedation. Disadvantages of CT scanning include radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to neuroimaging in children\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is generally the imaging modality of choice in patients with unexplained hydrocephalus, if it is readily available. MRI provides superior visualization of pathological processes in the cerebrospinal fluid (CSF) pathway, including CSF flow dynamics. There are numerous sequences, but few will provide useful information regarding hydrocephalus. T2-weighted imaging provides information regarding the CSF spaces and cisterns. Specific sequences such as Turbo-spin echo (TSE), three-dimensional constructive interference in the steady state (3D-CISS), and cine phase contrast (cine PC) have gained wide acceptance in evaluating CSF flow and anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to neuroimaging in children\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434050\">",
"    <span class=\"h3\">",
"     Obstructive versus communicating hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging can help to distinguish obstructive (non-communicating) from absorptive (communicating) hydrocephalus. This distinction informs treatment decisions about shunting versus third ventriculostomy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The site of obstructed CSF flow may be suggested by the pattern of ventricular dilatation. Stenosis of the aqueduct (a common type of obstructive hydrocephalus) typically results in dilated lateral and third ventricles and in a fourth ventricle of normal size. In contrast, communicating hydrocephalus (eg, caused by either extraventricular obstruction or by impaired CSF absorption) in neonates and infants usually results in symmetric dilatation of all four ventricles. If extraventricular obstruction or impaired CSF absorption occurs in children and adults, it may cause benign intracranial hypertension (pseudotumor cerebri) without ventricular dilatation, because of reduced compliance of the brain tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434043\">",
"    <span class=\"h3\">",
"     Hydrocephalus versus atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to differentiate hydrocephalus from ventriculomegaly due to cerebral atrophy (&ldquo;hydrocephalus ex-vacuo&rdquo;). The following characteristics are suggestive of hydrocephalus, rather than ventriculomegaly secondary to atrophic brain:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enlargement of the recesses of the third ventricle",
"     </li>",
"     <li>",
"      Dilation of the temporal horns of the lateral ventricle",
"     </li>",
"     <li>",
"      Interstitial edema of the periventricular tissues (seen on T2-weighted or FLAIR [fluid-attenuated inversion recovery] MRI sequences)",
"     </li>",
"     <li>",
"      Effacement of the cortical sulci",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434073\">",
"    <span class=\"h3\">",
"     Antenatal MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal MRI of the fetus is becoming a more common practice and is often used to further evaluate ventricular abnormalities detected by fetal ultrasonography. Ventriculomegaly is diagnosed if the ventricular atrium exceeds 10 mm at any gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/23\">",
"     23",
"    </a>",
"    ]. The posterior portion of the lateral ventricles is normally larger than the anterior portion in the fetus, and the discrepancy becomes less marked as the fetus approaches term. This configuration is called colpocephaly and is often misinterpreted as hydrocephalus by clinicians lacking experience in fetal imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20711018\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an infection causing adhesive arachnoiditis or ependymitis is suspected, a lumbar puncture (LP) should be performed, and the CSF should be examined. However, LP is contraindicated if the patient has evidence of a space-occupying lesion such as an intracranial tumor or a brain abscess, because of the risk of cerebral herniation. Thus, neuroimaging should be performed prior to LP in an infant or child with hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of hydrocephalus are progressive, meaning that neurological deterioration will occur if the hydrocephalus is not effectively and continuously treated. The most effective treatment is surgical drainage, using a shunt or third ventriculostomy. In cases of hydrocephalus caused by a vein of Galen malformation, embolization of the malformation may be more appropriate than surgical drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shunting can be effective for hydrocephalus caused either by obstruction or by impaired cerebrospinal fluid (CSF) absorption (communicating hydrocephalus). By contrast, third ventriculostomy is only effective for obstructive hydrocephalus; it may be the optimal procedure for obstructive hydrocephalus including aqueductal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/26\">",
"     26",
"    </a>",
"    ]. However, many types of hydrocephalus have both obstructive and absorptive components, so the selection of procedure is not always clear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, hydrocephalus is not progressive because alternate pathways of CSF absorption develop or because normal mechanisms for CSF handling become reestablished. This is known as &ldquo;arrested hydrocephalus.&rdquo; In this case, shunt revision is unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mechanical shunt system is placed to prevent the excessive accumulation of CSF. The shunt allows CSF to flow from the ventricles into the systemic circulation or to the peritoneum where it is absorbed, bypassing the site of mechanical or functional obstruction to absorption. Shunts consist of the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A catheter is placed into one of the lateral ventricles (usually the right).",
"     </li>",
"     <li>",
"      The catheter is connected to a one-way valve system (usually placed beneath the scalp of the postauricular area) that opens when the pressure in the ventricle exceeds a certain value. The ventricular pressure decreases as fluid drains, resulting in closure of the valve until the pressure increases again.",
"     </li>",
"     <li>",
"      The distal end of the system is connected to a catheter that is placed in the right atrium of the heart (ventriculoatrial [VA]) or into the peritoneal cavity (ventriculoperitoneal [VP]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, complications of treated hydrocephalus are due to malfunction of the shunt. If the shunt malfunctions and if the mechanism causing the hydrocephalus is still active, symptoms of hydrocephalus recur, and a shunt revision or other drainage procedure is required.",
"   </p>",
"   <p>",
"    Malfunction may be caused by infection or mechanical failure. Approximately 40 percent of standard shunts malfunction within the first year after placement, and 5 percent per year malfunction in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infection",
"      </strong>",
"      &mdash; Shunt infection is a common complication, occurring in approximately 5 to 15 percent of procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27,28,30\">",
"       27,28,30",
"      </a>",
"      ]. This may lead to ventriculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/31\">",
"       31",
"      </a>",
"      ], may promote the development of loculated compartments of CSF, and may contribute to impaired cognitive outcome and death [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"       27",
"      </a>",
"      ]. The risk of shunt infections may be higher in newborns compared with shunts placed in older infants and children [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Most shunt infections occur in the first six months after shunt placement. This is important in the algorithm of deciding when to tap shunts to evaluate a fever, especially when there is no clinical or radiographic evidence of mechanical shunt failure. Infection must be considered in a child with a shunt who develops persistent fever. Antibiotics should be started, but this treatment alone is usually not effective. In most cases, an infected shunt must be removed, and an external ventricular drain must temporarily be placed.",
"      <br/>",
"      <br/>",
"      Perioperative antibiotic prophylaxis may reduce the risk of infection. In a meta-analysis of 17 trials in 2134 participants, prophylactic antibiotics in the perioperative period and antibiotic-impregnated catheters reduced the risk of shunt infection by approximately 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/33\">",
"       33",
"      </a>",
"      ]. Whether prophylactic antibiotics are beneficial after the perioperative period remains uncertain.",
"     </li>",
"     <li>",
"      <strong>",
"       Mechanical failure",
"      </strong>",
"      &mdash; Mechanical shunt failure is another important cause of shunt failure. Like shunt infection, it is most common during the first year after shunt placement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"       27",
"      </a>",
"      ]. More than half of first shunt failures result from obstruction at the ventricular catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"       27",
"      </a>",
"      ]. One mechanism is excessive drainage of CSF (overdrainage), which greatly reduces the size of the ventricles. This causes the catheter to lie against the ependyma and choroid plexus, and these tissues block the holes at the end of the catheter. Fractured tubing is the cause of shunt failure in approximately 15 percent of cases. Other causes include migration of part or all of the shunt (7.5 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       Overdrainage",
"      </strong>",
"      &mdash; In addition to obstruction, overdrainage can cause functional shunt failure, which causes subnormal intracranial pressure (particularly in the upright position) and which is associated with characteristic neurological symptoms such as postural headache and nausea [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"       27",
"      </a>",
"      ]. Overdrainage can also lead to slit-ventricle syndrome, which is characterized by small or slit-like ventricles, coupled with transient episodes of symptoms of raised ICP. Changes in shunt design to address the problem of overdrainage include valves designed to open at different pressures and selected based upon the patient&rsquo;s characteristics; anti-siphoning devices to minimize the siphon effect caused by changes in posture; and valves that regulate by flow rather than by pressure differences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Third ventriculostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic third ventriculostomy (ETV) is a procedure in which a perforation is made to connect the third ventricle to the subarachnoid space. This has been used in the initial treatment of selected cases of obstructive hydrocephalus and as an alternative to shunt revision. Some experts consider it the treatment of choice for aqueductal stenosis, although about 20 percent of patients still require shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/26\">",
"     26",
"    </a>",
"    ]. ETV is not useful for patients with communicating hydrocephalus (due to impaired CSF absorption). The success of the procedure depends upon the cause of hydrocephalus and upon previous complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. When successful, ETV provides a treatment for hydrocephalus that is relatively low-cost and durable. In an observational study, the quality of life one year after the procedure was similar for patients treated with ETV compared with those treated with VP shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an analysis of 618 ETV procedures performed at 12 international institutions, the overall success of ETV was 66 percent six months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/38\">",
"     38",
"    </a>",
"    ]. Older age at the time of the procedure (eg, greater than one year of age) was by far the strongest predictor of success, and noninfectious etiologies (eg, myelomeningocele, intraventricular hemorrhage, aqueductal stenosis, or tectal tumor) and lack of previous shunt were also important predictors. Based upon these data, the investigators retrospectively developed and validated an ETV success score that predicts the likelihood of early success. For the patients with successful ETV at six months, more than 80 percent are still successful five years later. In a follow-up study, the same investigators found that the best ETV candidates (high ETV success score) had substantially better outcomes after ETV compared with shunt. By contrast, for those with a low ETV success score, the risk of ETV failure is initially higher than the risk of shunt failure but becomes lower than the risk of shunt failure six months after the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for selection of patients for ETV versus shunting are not fully established. In our practice, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We generally perform ETV for patients with fourth ventricular outlet obstruction or with clear aqueductal stenosis and for those with pineal region tumors and tectal tumors, because these respond well to ETV.",
"     </li>",
"     <li>",
"      We generally do not perform ETV in patients with a history of intraventricular hemorrhage, meningitis, or previous shunting, because the likelihood of success is low. However, if patients with these disorders also have acquired aqueductal stenosis, we generally attempt ETV prior to pursuing shunting, because we have had moderate success with this approach.",
"     </li>",
"     <li>",
"      We generally do not perform ETV in infants with obstructive hydrocephalus who are younger than three months of age, because the likelihood of success is around 25 percent in this age group, as compared with a 45 percent success rate in infants between three and six months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/40\">",
"       40",
"      </a>",
"      ] and with a success rate of 64 percent in those between 6 and 12 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of third ventriculostomy are mainly perioperative and include inability to complete the procedure, hemorrhage, hypothalamic dysfunction (diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion, or precocious puberty), meningitis, and cerebral infarction. In a systematic review, permanent morbidity after the procedure was 2.1 percent, and mortality was 0.22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ETV is performed, it is important to monitor the patient postoperatively with serial clinical examinations and imaging to determine if the procedure was successful. If the hydrocephalus progresses, a shunting procedure generally is performed, because repeating the ETV acutely is not likely to be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical treatment for hydrocephalus includes the use of diuretics, fibrinolysis, and serial lumbar punctures. These procedures have significant complications and are less effective than surgical treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Diuretics and fibrinolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diuretics",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    decrease CSF production. They have been used for short periods in slowly progressive hydrocephalus in patients too unstable for surgery.",
"   </p>",
"   <p>",
"    In newborn infants with posthemorrhagic hydrocephalus, treatment with diuretics is generally not effective and is associated with complications. Treatment with fibrinolytic agents has had mixed results in this group of patients and also is associated with significant complications. These issues are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link&amp;anchor=H17328774#H17328774\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\", section on 'Management of PHH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Serial lumbar punctures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated lumbar punctures have been used as a temporizing measure in preterm infants with post-hemorrhagic hydrocephalus, although they do not appear to be effective. In a systematic review of four trials, the relative risks for shunt placement, death, disability, and multiple disability were similar for repeated lumbar puncture and for supportive measures alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/42\">",
"     42",
"    </a>",
"    ]. However, drainage of CSF was considered a reasonable treatment when evidence of increased intracranial pressure exists. In cases of rapidly progressive hydrocephalus, a temporary ventricular drainage device (ventriculostomy) may be needed until a permanent shunt can be placed or until the hydrocephalus resolves spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link&amp;anchor=H17328774#H17328774\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\", section on 'Management of PHH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of hydrocephalus depends upon the etiology, the associated abnormalities, and the complications such as infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival in untreated hydrocephalus is poor. Approximately 50 percent of affected patients die before three years of age, and 77 to 80 percent die before reaching adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"     27",
"    </a>",
"    ]. Treatment markedly improves the outcome for hydrocephalus not associated with tumor, with 89 and 95 percent survival in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/32,45\">",
"     32,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur frequently in children with shunted hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In one report from France of 802 children treated with VP shunt and followed for a mean of eight years, 32 percent had epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/47\">",
"     47",
"    </a>",
"    ]. Seizures often started approximately at the time at which the diagnosis of hydrocephalus was made. However, shunt placement and complications also predisposed to epilepsy.",
"   </p>",
"   <p>",
"    The incidence of seizures varied according to the etiology of hydrocephalus. The risks in patients with infection, with cerebral malformations or intraventricular hemorrhage (IVH), and with spina bifida were approximately 50, 30, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures are associated with poor cognitive outcome. In the large French series, fewer children with seizures had normal cognition (intelligence quotient [IQ] &gt;90) compared with those without seizures (24 versus 66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/47\">",
"     47",
"    </a>",
"    ]. Seizures in this setting can be subclinical or can occur exclusively at night [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/48\">",
"     48",
"    </a>",
"    ]. Electroencephalogram (EEG) monitoring should be considered in patients with neurologic deterioration who do not appear to have shunt failure or infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Functional outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional outcome depends upon factors including degree of prematurity, central nervous system (CNS) malformations, other congenital abnormalities, and epilepsy, as well as sensory and motor impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"     27",
"    </a>",
"    ]. A Hydrocephalus Outcome Questionnaire has proven to be a useful tool to measure the physical, emotional, cognitive, and social function of hydrocephalic children, aspects of health that are often overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Few studies of long-term outcome are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from France, outcome at 10 years was evaluated in 129 consecutive children with hydrocephalus without tumor who had shunt placement before two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/45\">",
"       45",
"      </a>",
"      ]. Motor deficits, visual or auditory deficits, and epilepsy occurred in 60, 25, and 30 percent of patients, respectively. IQ was &gt;90 in 32 percent and was &lt;50 in 21 percent. Attendance at a normal school was possible for 60 percent, although one-half were one to two years behind for their age or were having difficulties. Of the remainder, 31 percent were in special classes or were institutionalized, and 9 percent were not considered educable.",
"     </li>",
"     <li>",
"      In a series from the United Kingdom, 155 children with shunted hydrocephalus were followed for 10 years or until death (which occurred in 11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/32\">",
"       32",
"      </a>",
"      ]. For survivors, until school age, 59 percent attended a normal school. Children with hydrocephalus caused by infection or by IVH were more likely to need special school than were those with congenital hydrocephalus (52 and 60 percent versus 29 percent).",
"     </li>",
"     <li>",
"      Cognitive outcome at 5 to 10 years of age was assessed in 73 children with hydrocephalus born in Sweden between 1989 and 1993 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/51\">",
"       51",
"      </a>",
"      ]. IQ was &ge;85 in 33 percent, 70 to 84 in 30 percent, 50 to 69 in 21 percent, and &lt;50 in 16 percent. Median IQ was decreased among those who were born preterm compared with term (median IQ score 68 versus 76); among those with isolated hydrocephalus at birth compared with those with hydrocephalus and myelomeningocele or with acquired hydrocephalus (median IQ score 60 versus 77); and among those with cerebral palsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epilepsy compared with those without (median IQ score 66 versus 78). There was a discrepancy between median verbal and performance IQ (90 and 76, respectively), which has been noted in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In extremely low-birthweight infants, hydrocephalus associated with intraventricular hemorrhage and a shunt correlated with adverse neurodevelopmental outcomes at 18 to 22 months follow-up, compared with children with and without severe intraventricular hemorrhage and with no shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?5/54/5994/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/9/44177?source=see_link\">",
"       \"Patient information: Hydrocephalus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2556103\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of hydrocephalus in children are caused by excess CSF accumulating in the cerebral ventricles due to disturbances of CSF circulation (known as obstructive or non-communicating hydrocephalus). Less often, the CSF accumulates because of impaired absorption (known as communicating hydrocephalus) or because of excessive CSF production. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Untreated hydrocephalus that begins in infancy before fusion of the cranial sutures typically results in marked enlargement of the head and in less destruction of brain tissue compared with hydrocephalus that develops acutely. This is because the skull expands, partially relieving the intracranial pressure. As hydrocephalus progresses, edema and ischemia develop in the periventricular brain tissue, leading to atrophy of the white matter. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common causes of congenital hydrocephalus include intraventricular hemorrhage and neural tube defects including myelomeningocele. Other causes include infection, genetic defects (X-linked hydrocephalus), trauma, tumors, and teratogens. These disorders can be grouped according to the primary pathogenic mechanism (obstructive versus absorptive) (",
"      <a class=\"graphic graphic_table graphicRef82965 \" href=\"UTD.htm?13/26/13741\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The signs and symptoms of hydrocephalus result from increased intracranial pressure (ICP) and dilatation of the ventricles. The time of presentation depends upon the acuity of the process. Symptoms of hydrocephalus are nonspecific and independent of the etiology. Headache is a prominent symptom; it tends to occur in the early morning and may be associated with nausea and vomiting. Affected patients often have changes in their personality and behavior. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hydrocephalus should be suspected in an infant whose head circumference is enlarged at birth or in whom serial measurements cross percentiles in standard growth curves, indicating excessive head growth. The diagnosis is confirmed by head ultrasonography in infants and by computerized tomography (CT) or magnetic resonance imaging (MRI) in older infants or children. Brain imaging can help to distinguish obstructive (non-communicating) from absorptive (communicating) hydrocephalus, and this information informs treatment decisions. (See",
"      <a class=\"local\" href=\"#H20710988\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of hydrocephalus are progressive, meaning that neurological deterioration will occur if the hydrocephalus is not effectively and continuously treated, using shunting or endoscopic third ventriculostomy (ETV). In general, ETV is the procedure of choice for pure obstructive hydrocephalus. Shunting is used for patients with communicating hydrocephalus or for those in whom ETV is not successful. However, many forms of hydrocephalus have both obstructive and absorptive components, so the outcome of ETV cannot be consistently predicted. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most complications of treated hydrocephalus are due to malfunction of the shunt. If the shunt malfunctions and if the mechanism causing the hydrocephalus is still active, symptoms of hydrocephalus recur, and a shunt revision or other drainage procedure is required. Shunt malfunction may be caused by infection or by mechanical failure. Approximately 40 percent of standard shunts malfunction within the first year after placement. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fishman MA. Hydrocephalus. In: Neurological pathophysiology, Eliasson SG, Prensky AL, Hardin WB (Eds), Oxford, New York 1978.",
"    </li>",
"    <li>",
"     Carey CM, Tullous MW, Walker ML. Hydrocephalus: Etiology, Pathologic Effects, Diagnosis, and Natural History. In: Pediatric Neurosurgery, 3 ed, Cheek WR (Ed), WB Saunders Company, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/3\">",
"      Hellbusch LC. Benign extracerebral fluid collections in infancy: clinical presentation and long-term follow-up. J Neurosurg 2007; 107:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/4\">",
"      Bateman GA, Napier BD. External hydrocephalus in infants: six cases with MR venogram and flow quantification correlation. Childs Nerv Syst 2011; 27:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/5\">",
"      Fernell E, Hagberg G, Hagberg B. Infantile hydrocephalus epidemiology: an indicator of enhanced survival. Arch Dis Child Fetal Neonatal Ed 1994; 70:F123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/6\">",
"      Jeng S, Gupta N, Wrensch M, et al. Prevalence of congenital hydrocephalus in California, 1991-2000. Pediatr Neurol 2011; 45:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/7\">",
"      Garne E, Loane M, Addor MC, et al. Congenital hydrocephalus--prevalence, prenatal diagnosis and outcome of pregnancy in four European regions. Eur J Paediatr Neurol 2010; 14:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/8\">",
"      Munch TN, Rostgaard K, Rasmussen ML, et al. Familial aggregation of congenital hydrocephalus in a nationwide cohort. Brain 2012; 135:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/9\">",
"      Yasuda T, Tomita T, McLone DG, Donovan M. Measurement of cerebrospinal fluid output through external ventricular drainage in one hundred infants and children: correlation with cerebrospinal fluid production. Pediatr Neurosurg 2002; 36:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/10\">",
"      Beni-Adani L, Biani N, Ben-Sirah L, Constantini S. The occurrence of obstructive vs absorptive hydrocephalus in newborns and infants: relevance to treatment choices. Childs Nerv Syst 2006; 22:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/11\">",
"      Schrander-Stumpel C, Fryns JP. Congenital hydrocephalus: nosology and guidelines for clinical approach and genetic counselling. Eur J Pediatr 1998; 157:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/12\">",
"      Graf WD, Born DE, Sarnat HB. The pachygyria-polymicrogyria spectrum of cortical dysplasia in X-linked hydrocephalus. Eur J Pediatr Surg 1998; 8 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/13\">",
"      Fransen E, Van Camp G, Vits L, Willems PJ. L1-associated diseases: clinical geneticists divide, molecular geneticists unite. Hum Mol Genet 1997; 6:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/14\">",
"      Sasaki-Adams D, Elbabaa SK, Jewells V, et al. The Dandy-Walker variant: a case series of 24 pediatric patients and evaluation of associated anomalies, incidence of hydrocephalus, and developmental outcomes. J Neurosurg Pediatr 2008; 2:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/15\">",
"      Frawley GP, Dargaville PA, Mitchell PJ, et al. Clinical course and medical management of neonates with severe cardiac failure related to vein of Galen malformation. Arch Dis Child Fetal Neonatal Ed 2002; 87:F144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/16\">",
"      Akins PT, Guppy KH, Axelrod YV, et al. The genesis of low pressure hydrocephalus. Neurocrit Care 2011; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/17\">",
"      Kirkpatrick M, Engleman H, Minns RA. Symptoms and signs of progressive hydrocephalus. Arch Dis Child 1989; 64:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/18\">",
"      Alexander E Jr, Davis CH. Macewen's sign--\"the cracked pot sound\". Surg Neurol 1987; 27:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/19\">",
"      L&ouml;pp&ouml;nen T, Saukkonen AL, Serlo W, et al. Accelerated pubertal development in patients with shunted hydrocephalus. Arch Dis Child 1996; 74:490.",
"     </a>",
"    </li>",
"    <li>",
"     Rekate HL. Treatment of Hydrocephalus. In: Pediatric Neurosurgery, 3, Cheek WR (Ed), WB Saunders Company, Philadelphia 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/21\">",
"      Brunetti MA, Mahesh M, Nabaweesi R, et al. Diagnostic radiation exposure in pediatric trauma patients. J Trauma 2011; 70:E24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/22\">",
"      Din&ccedil;er A, &Ouml;zek MM. Radiologic evaluation of pediatric hydrocephalus. Childs Nerv Syst 2011; 27:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/23\">",
"      Cavalheiro S, Moron AF, Almodin CG, et al. Fetal hydrocephalus. Childs Nerv Syst 2011; 27:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/24\">",
"      Jea A, Bradshaw TJ, Whitehead WE, et al. The high risks of ventriculoperitoneal shunt procedures for hydrocephalus associated with vein of Galen malformations in childhood: case report and literature review. Pediatr Neurosurg 2010; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/25\">",
"      Schneider SJ, Wisoff JS, Epstein FJ. Complications of ventriculoperitoneal shunt procedures or hydrocephalus associated with vein of Galen malformations in childhood. Neurosurgery 1992; 30:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/26\">",
"      Cinalli G, Spennato P, Nastro A, et al. Hydrocephalus in aqueductal stenosis. Childs Nerv Syst 2011; 27:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/27\">",
"      Chumas P, Tyagi A, Livingston J. Hydrocephalus--what's new? Arch Dis Child Fetal Neonatal Ed 2001; 85:F149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/28\">",
"      Drake JM, Kestle JR, Milner R, et al. Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus. Neurosurgery 1998; 43:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/29\">",
"      Stein SC, Guo W. Have we made progress in preventing shunt failure? A critical analysis. J Neurosurg Pediatr 2008; 1:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/30\">",
"      Langley JM, LeBlanc JC, Drake J, Milner R. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis 1993; 17:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/31\">",
"      Forward KR, Fewer HD, Stiver HG. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J Neurosurg 1983; 59:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/32\">",
"      Casey AT, Kimmings EJ, Kleinlugtebeld AD, et al. The long-term outlook for hydrocephalus in childhood. A ten-year cohort study of 155 patients. Pediatr Neurosurg 1997; 27:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/33\">",
"      Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev 2006; :CD005365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/34\">",
"      Siomin V, Cinalli G, Grotenhuis A, et al. Endoscopic third ventriculostomy in patients with cerebrospinal fluid infection and/or hemorrhage. J Neurosurg 2002; 97:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/35\">",
"      Scarrow AM, Levy EI, Pascucci L, Albright AL. Outcome analysis of endoscopic III ventriculostomy. Childs Nerv Syst 2000; 16:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/36\">",
"      Javadpour M, Mallucci C, Brodbelt A, et al. The impact of endoscopic third ventriculostomy on the management of newly diagnosed hydrocephalus in infants. Pediatr Neurosurg 2001; 35:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/37\">",
"      Drake JM, Kulkarni AV, Kestle J. Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in pediatric patients: a decision analysis. Childs Nerv Syst 2009; 25:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/38\">",
"      Kulkarni AV, Drake JM, Mallucci CL, et al. Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus. J Pediatr 2009; 155:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/39\">",
"      Kulkarni AV, Drake JM, Kestle JR, et al. Predicting who will benefit from endoscopic third ventriculostomy compared with shunt insertion in childhood hydrocephalus using the ETV Success Score. J Neurosurg Pediatr 2010; 6:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/40\">",
"      Ogiwara H, Dipatri AJ Jr, Alden TD, et al. Endoscopic third ventriculostomy for obstructive hydrocephalus in children younger than 6 months of age. Childs Nerv Syst 2010; 26:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/41\">",
"      Bouras T, Sgouros S. Complications of endoscopic third ventriculostomy: a systematic review. Acta Neurochir Suppl 2012; 113:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/42\">",
"      Whitelaw A. Repeated lumbar or ventricular punctures in newborns with intraventricular hemorrhage. Cochrane Database Syst Rev 2001; :CD000216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/43\">",
"      Berger A, Weninger M, Reinprecht A, et al. Long-term experience with subcutaneously tunneled external ventricular drainage in preterm infants. Childs Nerv Syst 2000; 16:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/44\">",
"      Heep A, Engelskirchen R, Holschneider A, Groneck P. Primary intervention for posthemorrhagic hydrocephalus in very low birthweight infants by ventriculostomy. Childs Nerv Syst 2001; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/45\">",
"      Hoppe-Hirsch E, Laroussinie F, Brunet L, et al. Late outcome of the surgical treatment of hydrocephalus. Childs Nerv Syst 1998; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/46\">",
"      Klepper J, B&uuml;sse M, Strassburg HM, S&ouml;rensen N. Epilepsy in shunt-treated hydrocephalus. Dev Med Child Neurol 1998; 40:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/47\">",
"      Bourgeois M, Sainte-Rose C, Cinalli G, et al. Epilepsy in children with shunted hydrocephalus. J Neurosurg 1999; 90:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/48\">",
"      Caraballo RH, Bongiorni L, Cers&oacute;simo R, et al. Epileptic encephalopathy with continuous spikes and waves during sleep in children with shunted hydrocephalus: a study of nine cases. Epilepsia 2008; 49:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/49\">",
"      Kulkarni AV, Donnelly R, Shams I. Comparison of Hydrocephalus Outcome Questionnaire scores to neuropsychological test performance in school-aged children. J Neurosurg Pediatr 2011; 8:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/50\">",
"      Kulkarni AV, Drake JM, Rabin D, et al. Measuring the health status of children with hydrocephalus by using a new outcome measure. J Neurosurg 2004; 101:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/51\">",
"      Lindquist B, Carlsson G, Persson EK, Uvebrant P. Learning disabilities in a population-based group of children with hydrocephalus. Acta Paediatr 2005; 94:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/52\">",
"      Brookshire BL, Fletcher JM, Bohan TP, et al. Verbal and nonverbal skill discrepancies in children with hydrocephalus: a five-year longitudinal follow-up. J Pediatr Psychol 1995; 20:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/54/5994/abstract/53\">",
"      Adams-Chapman I, Hansen NI, Stoll BJ, et al. Neurodevelopmental outcome of extremely low birth weight infants with posthemorrhagic hydrocephalus requiring shunt insertion. Pediatrics 2008; 121:e1167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6174 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5994=[""].join("\n");
var outline_f5_54_5994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2556103\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2169815\">",
"      CSF production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CSF circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CSF absorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Impaired absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Excessive production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Isolated hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - X-linked hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - CNS malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Syndromic forms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intrauterine infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H434112\">",
"      - Choroid plexus papilloma or carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Acquired hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20710834\">",
"      - Infections and tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20710841\">",
"      - Posthemorrhagic hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2169911\">",
"      Low pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20710988\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H434050\">",
"      - Obstructive versus communicating hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H434043\">",
"      - Hydrocephalus versus atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H434073\">",
"      - Antenatal MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20711018\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Third ventriculostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Diuretics and fibrinolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Serial lumbar punctures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Functional outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2556103\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6174|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/58/10144\" title=\"diagnostic image 1\">",
"      Aqueductal stenosis due to a tectal lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/62/40928\" title=\"diagnostic image 2\">",
"      Hydrocephalus due to a Chiari II malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/15/39155\" title=\"diagnostic image 3\">",
"      MRI brain Chiari II malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/55/18294\" title=\"diagnostic image 4\">",
"      Hydrocephalus associated with Dandy Walker malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/46/24290\" title=\"diagnostic image 5\">",
"      Hydrocephalus due to a vein of Galen malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/24/14720\" title=\"diagnostic image 6\">",
"      Hydrocephalus due to a choroid plexus papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/2/17441\" title=\"diagnostic image 7A\">",
"      Hydrocephalus due to germinal matrix intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/0/16399\" title=\"diagnostic image 7B\">",
"      Post hemorrhagic hydrocephalus sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6174|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/9/39063\" title=\"figure 1\">",
"      Subarachnoid spaces and cisterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6174|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/19/16695\" title=\"picture 1\">",
"      Parinaud syndrome 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6174|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/26/13741\" title=\"table 1\">",
"      Obstructive vs absorptive hydrocephalus in infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/52/12107\" title=\"table 2\">",
"      Parinaud syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/3/5179\" title=\"table 3\">",
"      Cutaneous syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=related_link\">",
"      Chiari malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20921?source=related_link\">",
"      Pathogenesis and types of occult spinal dysraphism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/9/44177?source=related_link\">",
"      Patient information: Hydrocephalus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=related_link\">",
"      Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3991?source=related_link\">",
"      Primary (congenital) encephalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35560?source=related_link\">",
"      Ultrasound diagnosis of neural tube defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_54_5995="Fetal age by foot length";
var content_f5_54_5995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gestational age based upon fetal foot length",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Foot length, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5995=[""].join("\n");
var outline_f5_54_5995=null;
var title_f5_54_5996="Followup prosthetic heart valve";
var content_f5_54_5996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Serial monitoring in patients with prosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following tests should be performed during follow-up in patients with prosthetic heart valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; At the first post-operative outpatient visit two to four weeks after hospital discharge:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Interval history, physical examination, and appropriate blood tests (complete blood count, creatinine, electrolytes, lactate dehydrogenase, and INR if indicated), and, if not obtained before hospital discharge, a baseline transthoracic Doppler echocardiogram.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Follow-up visits:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Routine follow-up visits occur yearly in asymptomatic patients. The evaluation should include a complete history and physical examination and other tests as indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Repeat evaluation with echocardiography any time there is a change in clinical status.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following test in patients with prosthetic heart valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In patients with bioprosthetic valves who do not have a change in clinical status, routine annual echocardiography after the first five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following test should NOT be performed in patients with prosthetic heart valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In the absence of a change in clinical status, routine annual echocardiography in patients with mechanical valves or during the first five years in patients with bioprosthetic valves.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5996=[""].join("\n");
var outline_f5_54_5996=null;
var title_f5_54_5997="Hereditary periodic fevers";
var content_f5_54_5997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The periodic fever syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Disease",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gene Locus",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age of onset",
"      </td>",
"      <td class=\"subtitle1\">",
"       Inher- itance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ethnicity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Length of fevers",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Amyloid",
"      </td>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FMF",
"      </td>",
"      <td>",
"       MEFV",
"      </td>",
"      <td>",
"       &lt;20 y",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       <p>",
"        Sephardic Jews Armenians",
"       </p>",
"       <p>",
"        Turks",
"       </p>",
"       <p>",
"        Arabs",
"       </p>",
"       <p>",
"        Ashkenazi Jews",
"       </p>",
"      </td>",
"      <td>",
"       1-3d",
"      </td>",
"      <td>",
"       <p>",
"        Abdominal pain",
"       </p>",
"       <p>",
"        Pleurisy",
"       </p>",
"       <p>",
"        Arthralgia/arthritis",
"       </p>",
"       <p>",
"        Scrotal swelling",
"       </p>",
"       <p>",
"        Erysipeloid rash",
"       </p>",
"      </td>",
"      <td>",
"       &gt;20* percent",
"      </td>",
"      <td>",
"       Mutational testing",
"      </td>",
"      <td>",
"       Colchicine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TRAPS",
"      </td>",
"      <td>",
"       TNFR1",
"      </td>",
"      <td>",
"       &lt;20 y",
"      </td>",
"      <td>",
"       AD",
"      </td>",
"      <td>",
"       <p>",
"        Irish Scottish",
"       </p>",
"       <p>",
"        other",
"       </p>",
"      </td>",
"      <td>",
"       &gt;5d",
"      </td>",
"      <td>",
"       <p>",
"        Conjunctivitis",
"       </p>",
"       <p>",
"        Abdominal pain",
"       </p>",
"       <p>",
"        Regional myalgia",
"       </p>",
"       <p>",
"        Arthralgia/arthritis",
"       </p>",
"       <p>",
"        Rash",
"       </p>",
"      </td>",
"      <td>",
"       25 percent",
"      </td>",
"      <td>",
"       Mutational testing",
"      </td>",
"      <td>",
"       <p>",
"        Glucocorticoids",
"       </p>",
"       <p>",
"        Etanercept",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIDS",
"      </td>",
"      <td>",
"       MEVK",
"      </td>",
"      <td>",
"       &lt;1 y",
"      </td>",
"      <td>",
"       AR",
"      </td>",
"      <td>",
"       <p>",
"        Dutch French",
"       </p>",
"       <p>",
"        other",
"       </p>",
"      </td>",
"      <td>",
"       3-7d",
"      </td>",
"      <td>",
"       <p>",
"        Cervical lymph- adenopathy",
"       </p>",
"       <p>",
"        Abdominal pain",
"       </p>",
"       <p>",
"        Arthralgia/arthritis",
"       </p>",
"       <p>",
"        Rash",
"       </p>",
"       <p>",
"        Splenomegaly",
"       </p>",
"      </td>",
"      <td>",
"       rare",
"      </td>",
"      <td>",
"       <p>",
"        Serum IgD &gt;100 IU/ml",
"       </p>",
"       <p>",
"        IgA elevated &gt;80 percent",
"       </p>",
"       <p>",
"        Mutational testing for V377I (&gt;80 percent)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        NSAIDs",
"       </p>",
"       <p>",
"        Glucocorticoids",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PFAPA",
"      </td>",
"      <td>",
"       unknown",
"      </td>",
"      <td>",
"       &lt;5 y",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       any",
"      </td>",
"      <td>",
"       3-4d",
"      </td>",
"      <td>",
"       <p>",
"        Cervical lymph- adenopathy",
"       </p>",
"       <p>",
"        Aphthous stomatitis",
"       </p>",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       none",
"      </td>",
"      <td>",
"       <p>",
"        Glucocorticoids",
"       </p>",
"       <p>",
"       </p>",
"       <p>",
"        Tonsillectomy",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FMF: familial Mediterranean fever; TRAPS: tumor necrosis factor alpha receptor 1 associated syndrome; HIDS: hyperimmunoglobulin D syndrome; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis; MEFV: pyrin/marenostrin gene located on chromosome 16p; TNFR1: tumor necrosis factor alpha receptor-1 gene located on chromosome 12 p; MEVK: mevalonate kinase gene located on chromosome 12q; AR: autosomal recessive; AD: autosomal dominant.",
"     <br>",
"      * 60 percent in an untreated Armenian population with FMF.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5997=[""].join("\n");
var outline_f5_54_5997=null;
var title_f5_54_5998="Administering cephalosporins to a historically allergic patient";
var content_f5_54_5998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Administration of a cephalosporin to a patient with a history of an immediate allergic reaction to another cephalosporin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Figure 1 in Ann Allergy Asthma Immunol 1999; 83: Suppl. Copyright &copy; 1999 American College of Allergy, Asthma and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5998=[""].join("\n");
var outline_f5_54_5998=null;
var title_f5_54_5999="Extrahepatic PSC US";
var content_f5_54_5999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extrahepatic primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of the right upper quadrant in a patient with ulcerative colitis and primary sclerosing cholangitis shows marked thickening of the wall of the common bile duct (large arrows) and narrowing of its lumen (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_54_5999=[""].join("\n");
var outline_f5_54_5999=null;
     